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Abstract 
Purpose: Pterygium is characterised as invasive, proliferative fibrovascular altered 
conjunctival tissue. The extensive vascular network is likely to significantly contribute 
to the progression of the disease. In the present study we investigated the effects of 
reduced serum (to mimic a suppressed blood supply) and treatment with 
transforming growth factor β on cell signalling and function of pterygial derived 
fibroblasts.  
Methods: Pure fibroblast cultures were established from cell outgrowths of pterygial 
tissue. Immunochemistry techniques were used to identify cell phenotype, tissue 
features and cell signalling. Growth and migration of pterygial-derived fibroblast 
were evaluated using a patch growth assay, MTS assay and a scratch wound assay. 
Intracellular calcium levels were determined using Fura-2 detection in response to 
ligand stimulation using a 96-well plate format. RT-PCR and Western blot were 
utilized to detect cell transdifferentiation. Human angiogenesis protein array was 
used for investigating angiogenic activities in pterygial fibroblasts. Gene microarray 
was employed to provide a global profile of gene expression in unstimulated and 
treated (1ng/ml TGFβ2 and 10% serum) conditions.  
Results: A progressive increase in serum level resulted in promotion of pterygial cell 
growth. A significant increase in intracellular calcium level was observed in response 
to histamine, ATP, acetylcholine and epidermal growth factor in serum-maintained 
cells. However, no significant changes were observed when cells were maintained in 
serum-free medium. 1M thapsigargin induced a significantly greater increase in 
intracellular calcium level in the serum maintained group relative to serum starved 
cells. Pre-incubation of cells with 1M thapsigargin ablated ligand-induced calcium 
responses. Disruption of calcium signalling through thapsigargin treatment 
significantly perturbed cell growth and migration. Smad2/Smad3 translocated to the 
nucleus in response to TGFβ in pterygial fibroblasts. TGFβ2 stimulated 
transdifferentiation of pterygial fibroblasts to myofibroblasts. Proteome Profiler™ 
Array data revealed that pterygial fibroblasts release angiogenic factors including IL-8 
and VEGF following treatment with 10% serum and TGFβ2. Gene microarray 
demonstrated that a total of 103 genes were up-regulated and 53 genes 
downregulated by more than 2 fold in pterygial fibroblast treated with 10% serum. A 
total of 198 genes were up-regulated and 197 genes were down-regulated by more 
than 2 fold in pterygial fibroblast exposed to TGFβ2.  
Conclusions: Calcium signalling was suppressed in pterygial-derived fibroblasts in 
response to serum-deprivation. The store plays a key role in cell growth and 
migration of pterygial derived fibroblasts. TGFβ induce the Smad signalling pathway 
and transdifferentiation in pterygial derived fibroblasts. Pterygial fibroblasts release a 
number of angiogenic factors and up-regulate transdifferentiation genes in response 
to serum or TGFβ2. Serum level/blood supply and TGFβ2 are likely to play a key role 
in the pathogenesis of pterygium. 
  
III 
 
 
 
TABLE OF CONTENT 
Acknowledgements 
Abstract 
Abbreviations 
CHAPTER 1 General introduction ............................................................................... 1 
1.1 Pterygium ............................................................................................................. 1 
1.2 Ultraviolet radiation and pterygium ...................................................................... 4 
1.3 Physiological features of pterygium ...................................................................... 5 
1.3.1 Inflammation ..................................................................................................... 5 
1.3.2 Cell proliferation and migration ......................................................................... 6 
1.3.3 Angiogenesis ...................................................................................................... 7 
1.3.4 Transdifferentiation ........................................................................................... 9 
1.3.5 Extracellular matrix remodelling ...................................................................... 10 
1.4 Calcium signalling ................................................................................................ 11 
1.4.1 Intracellular Calcium ........................................................................................ 11 
1.4.2 Receptor mediated pathway ............................................................................ 12 
1.5 Transforming growth factor beta signalling ......................................................... 15 
1.6 Genetic factors, viral infections and pterygium ................................................... 19 
1.7 Aim ..................................................................................................................... 20 
CHAPTER 2 Materials and methods.......................................................................... 21 
2.1 Tissue culture ...................................................................................................... 21 
2.1.1 Isolation and culture of pterygial-derived fibroblasts ....................................... 21 
2.1.2 Storing and recovering the cells ....................................................................... 24 
2.1.4 Photomicroscopy ............................................................................................. 24 
  
IV 
 
2.2 Histology ............................................................................................................. 25 
2.2.1 Paraffin embedding and slicing the sample ...................................................... 25 
2.2.2 Hematoxylin and eosin stain (H&E stain) .......................................................... 25 
2.2.3 Immunohistochemistry .................................................................................... 26 
2.2.4 Immunocytochemistry ..................................................................................... 27 
2.3 MTS assay ........................................................................................................... 29 
2.4 Scratch wound assay ........................................................................................... 30 
2.5 Calcium signalling ................................................................................................ 30 
2.6 Patch growth assay ............................................................................................. 33 
2.7 RT-PCR ................................................................................................................ 35 
2.7.1 RNA Extraction ................................................................................................. 35 
2.7.2 Synthesis of cDNA ............................................................................................ 36 
2.7.3 QRT-Polymerase chain reaction ....................................................................... 36 
2.8 Western blot analysis .......................................................................................... 38 
2.8.1 Protein extraction ............................................................................................ 38 
2.8.2 BCA protein assay ............................................................................................ 38 
2.8.3 SDS-PAGE gel electrophoresis and protein transfer .......................................... 39 
2.8.4 Immunoblotting and development ................................................................... 40 
2.9 Proteome Profiler™ Array ................................................................................... 41 
2.10 Illumina Gene Array .......................................................................................... 43 
CHAPTER 3 Serum deprivation can suppress calcium cell signalling in pterygial 
derived fibroblasts ................................................................................................... 45 
3.1 Introduction ........................................................................................................ 45 
3.2 Results ................................................................................................................ 47 
3.2.1 Clinical features of conjunctival and pterygial tissues ....................................... 47 
3.2.2 Concentration-dependent effects of serum on cell growth .............................. 47 
3.2.3 Intracellular calcium signalling ......................................................................... 50 
3.2.4 The effects of calcium signalling disruption on cell growth and migration ........ 62 
  
V 
 
3.2.5 Genes up-regulated and down-regulated by 10% serum in pterygial derived 
fibroblasts ................................................................................................................. 66 
3.2.6 Gene expression profile of histaminergic, purinergic, cholinergic and EGF 
receptors in pterygial fibroblasts .............................................................................. 66 
3.2.7 Angiogenesis factors expression ....................................................................... 70 
3.3 Discussion ........................................................................................................... 73 
CHAPTER 4 TGFβ signalling in pterygial fibroblasts .................................................. 84 
4.1 Introduction ........................................................................................................ 84 
4.2 Results ................................................................................................................ 85 
4.2.1 TGFβ/Smad signalling in pterygial fibroblasts ................................................... 85 
4.2.2 Transdifferentiation of pterygial fibroblasts ..................................................... 91 
4.2.3 Angiogenic factors expression .......................................................................... 94 
4.2.4 Gene array ....................................................................................................... 97 
4.3 Discussion ......................................................................................................... 108 
CHAPTER 5 Summary and future work ................................................................... 117 
References ............................................................................................................. 128 
APPENDIX I  Gene Microarray: 10% serum and TGFβ2 regulated gene expression 
data ........................................................................................................................ 146 
APPENDIX II Proteome Profiler: human angiogenesis array................................... 177 
 
 
 
 
 
 
 
 
 
 
  
VI 
 
 
Abbreviations 
 
AAH           Artificial aqueous humour 
ACh         Acetylcholine 
ADP           Adenosine Diphosphate 
ATP           Adenosine Triphosphate 
AM            Acetoxymethylester 
DAG           Diacylglycerol 
DAPI           4, 6-diamidino-2-phenylindole 
BCA             Bicinchoninic acid assay  
DMSO          Dimethyl sulfoxide  
DPBS           Dulbecco’s Phosphate Buffered Saline  
ECM           Extracellular matrix 
EDTA           Ethlenediaminetet raacetic acid  
  EMEM          Eagle’s minimum essential medium  
EGF            Epidermal growth factor  
EGFR           Epidermal growth factor receptor 
ER             Endoplasmic reticulum 
ERK            Extracellular signal-regulated kinase 
  
VII 
 
FCS            foetal calf serum 
GAPDH         Glyceraldehyde-3-phosphate 
GPCR           G-protein coupled receptor 
HEPES          hydroxyethyl piperazine ethanesulfonic acid  
IgG            Immunoglobulin gamma 
IP3             Inositol (1, 4, 5) trisphosphate 
IL             Interluekin 
MAPK          Mitogen-activated protein kinase 
M-PER         mammalian protein extraction reagent  
MMP          Matrx metalloproteinase 
PBS           Phosphate buffered saline 
PI3            Phosphatidylinositol 3 
PIP2           Phosphatidyl inositol 4, 5-bisphosphate 
PLC            Phospholipase C 
PVDF           polyvinylidene difluoride 
RT             Room temperature 
RT-PCR         Reverse transcriptase-polymerase chain reaction 
SEM           Standard error mean 
SF             Serum free 
ΑSMA          Alpha smooth muscle actin 
SMAD          Small body size mothers against DDP 
  
VIII 
 
Tg             Thapsigargin 
TGF            Transforming growth factor 
  
 
 
1 
 
CHAPTER 1 
General introduction 
 
 
1.1 Pterygium 
Pterygium is characterized as invasive, proliferative fibrovascular altered conjunctival 
tissue and fleshy outgrow over the cornea. It is triangular shaped fibrovascular tissue 
on the epibulbar conjunctiva surface (figure 1.1). Pterygium grows most commonly 
from the nasal aspect of the sclera, proliferating on the naso-temporal. It is linked 
and thought to be caused by ultraviolet radiation (UVR), low humidity, and dust 
(Coroneo 1993). It is also related to other long-term chronic stimulus. In terms of its 
shape, pterygium is divided into three component regions. The first region is known 
as the head and is the portion that is seen growing on the cornea. The second 
component is termed the neck, which is appears as a small bulge located in the 
cornea-scleral limbus region. The final part is the main body, which extends across 
the sclera surface. Pterygium is characterized as a highly vascular tissue. Reports 
suggest vascular endothelial growth factor (VEGF) is highly expressed and more von 
Willebrand factor (vWF) is stained in new vessels in pterygium tissue compared with 
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normal conjunctiva (Marcovich, Morad et al. 2002). Therefore, angiogenesis is likely 
to play a role in pterygium (Marcovich, Morad et al. 2002; Aspiotis, Tsanou et al. 
2007). The symptoms of pterygium include visual impairment when it invades the 
cornea, histogenesis degeneration, hypertrophy, hyperplasia, persistent redness, 
inflammation, foreign body sensation, dry eyes. 
 
Pterygium can cause inflammation, irritation and may affect vision by inducing 
astigmatism or involvement of the visual axis. Pterygium has some tumour-like 
features like invading normal tissue and high recurrence rates after surgical removal. 
Although the pathogenesis of pterygium is unclear, the effect of ultraviolet (UV) 
exposure leading to limbal epithelial cell damage is commonly accepted as involved 
(Coroneo 1993; Coroneo, Di Girolamo et al. 1999). Pterygium is also associated with 
hypersensitive reactions, accelerated fibroblastic proliferation (Hill and Maske 1989) 
and it is suggested that pterygium is the result of subconjunctival  invasion of 
fibroblasts that enter the cornea along natural tissue planes surrounding Bowman's 
layer (Cameron 1983). Furthermore, inflammatory cell infiltration and overexpression 
of extracellular matrix with alteration of the collagen and elastic fibres are also 
contributing factors (Cameron 1983; Karukonda, Thompson et al. 1995; Coroneo, Di 
Girolamo et al. 1999). In addition, heredity is also reported to play a role in pterygium 
(Hilgers 1960).  
 
  
 
 
3 
 
 
 
 
 
 
 
Figure 1.1. Pterygium formation in a patient. Note the triangular shape and extensive 
blood supply. Adapted from doctor.eye999.com/ 20080911/10280313.shtml 
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Today the choice of treatment for pterygium is controversial. A variety of options are 
available for the management of pterygium. At present, static type pterygium which 
has not violated the cornea and affected vision do not require surgery. If 
complications arise such as trachoma or chronic conjunctivitis, antibiotics or steroid 
eye drops can be used. If the pterygium covers the pupil, obstructs vision or presents 
with acute symptoms, current therapeutic approaches often employ conjunctival 
autografting, sliding conjunctival flaps, excimer laser treatment, and amniotic 
membrane transplants (Hirst 2003). In addition, due to the high recurrence rate, 
adjunctive therapies like radiation therapy (Nishimura, Nakai et al. 2000), 
intraoperative and postoperative mitomycin (Fruchtpery and Ilsar 1994; Lam, Wong 
et al. 1998) have been employed for preventing recurrence of pterygium.  
 
1.2 Ultraviolet radiation and pterygium 
 
It has been reported Ultraviolet radiation leads to limbal epithelial cell damage and 
induces the pterygium progression (Coroneo 1993; Coroneo, Di Girolamo et al. 1999).  
It showed dose dependent association between the ocular solar radiation and 
pterygium (Threlfall and English 1999). There are a number of epidemiological studies 
support the link between sun exposure and pterygium (McCarty, Fu et al. 2000; Paula, 
Thorn et al. 2006; Rim, Nam et al. 2013). Therefore, pterygium occurs frequently in 
tropical and equatorial climates. Many investigations confirmed a large number of 
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cases, outdoor workers (such as farmers, fishermen, pastoralists, etc.) who 
experience long-term radiation of sunlight, dust, snow and other stimulus result in 
the development of pterygium (Khoo, Saw et al. 1998; Wong, Foster et al. 2001; 
Al-Bdour and Al-Latayfeh 2004). Interestingly, the shadow of the nose partly reduces 
the intensity of sunlight focused on the lateral temporal limbus, thus pterygium 
normally occurs in nasal side (Coroneo 1993). The focal limbal irradiation may 
activate stem cells in the limbus (Di Girolamo, Chui et al. 2004) and UVB may induce 
the matrix metalloproteinases (MMPs) expression which result in extracellular matrix 
remodelling in development of pterygium through the extracellular signal-regulated 
kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) intracellular pathway (Di 
Girolamo, Coroneo et al. 2003). It has been reported UVB increases various 
chemokines, cytokines and growth factors like IL-6, IL-8, and VEGF production in 
pterygium via MAPK pathway (Di Girolamo, Wakefield et al. 2006). 
  
1.3 Physiological features of pterygium 
1.3.1 Inflammation 
Inflammation is a process of self-protection in human body to remove irritation. It 
happens in both normal physiological process like wound healing and pathology of 
disease like cancer. Chronic inflammation is from long-term irritation and consistently 
interferes with healthy tissues. It leads to increased blood flow, capillary permeability 
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elevation and induces white blood cell recruitment, which in turn release 
pro-inflammatory chemicals to results in angiogenesis (Leibovich, Polverini et al. 1987; 
Mantovani, Allavena et al. 2008). The chronic inflammatory process is an important 
characteristic in pterygium progression (Coroneo, Di Girolamo et al. 1999). UV light 
exposure promotes this inflammatory response by release of pro-inflammatory 
cytokines (Kennedy, Kim et al. 1997). Pterygial fibroblasts show increasing 
pro-inflammatory factors and their receptors (Chen, Tsai et al. 1994; Kria, Ohira et al. 
1998). EGFR phosphorylation, NF-kappaB activation and increasing production of IL-1, 
IL-6, IL-8, and TNF alpha were detected in UV-mediated corneal cells (Kennedy, Kim 
et al. 1997; Song, Abraham et al. 2002). It was reported that pterygial cell responses 
with certain growth factors like EGF, TGF-alpha, IL-1 beta, bFGF, TGF-beta 1, 
TNF-alpha, or IL-6 to induce secretion of proinflammatory cytokines expression of 
MMPs. MMPs subsequently activate ECM remodelling, angiogenesis and fibroblast 
proliferation in pterygium (Soloman, Li et al. 2000). The end result of chronic 
inflammation is tissue fibrosis which is defined as cell proliferation and excessive 
extracellular matrix deposition (Wynn 2008).  
 
1.3.2 Cell proliferation and migration 
In normal conditions, cell growth refers to cell development and cell division. There 
are four phases of the cell cycle, which regulates cell division. These phases are G1, S, 
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G2 and M phase (mitosis). In division, one cell will produce two cells (Schafer 1998). 
Deregulation of cell proliferation is the hallmark in many cancers with cell 
overgrowth and increased cell division the result (Sherr 1996; Levine 1997). However, 
ultraviolet radiation exposure or other stimuli can induce conjunctival epithelial to 
undergo abnormal growth (proliferation) to produce excessive cells along the nasal 
limbus in the progression of pterygium (Kwok and Coroneo 1994). Cell migration is 
defined as the movement of cells to specific positions and is critical in tissue 
formation. Migration also plays an important role during wound healing responses 
(Martin 1997). Altered basal limbal epithelial cell migration is described as a key 
feature of pterygium formation (Dushku, John et al. 2001). 
 
 
1.3.3 Angiogenesis 
Angiogenesis is an important physiological process occurring in the human body with 
the growth of new blood vessels from pre-existing vessels in response to tissue 
demands (Risau 1997). It is a normal process in growth and development such as 
wound healing and dysregulation of angiogenesis also impacts on human health 
(Carmeliet 2003). Angiogenesis-dependent diseases result when new blood vessels 
either grow excessively or insufficiently. Excessive angiogenesis occurs when diseased 
cells produce overwhelming angiogenic growth factors. It results in diseases such as 
cancer, infectious disease and age-related macular degeneration (Meyer, Clauss et al. 
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1999; Coussens and Werb 2002). In the case of cancer, the tumour recruits new 
blood vessels to support cell growth, surround the new capillary sprouts and 
metastases (Folkman 1995) and insufficient angiogenesis occurs in diseases such as 
stroke, heart and brain ischemia and hypertension (Boudier 1999; Kalimo, Ruchoux et 
al. 2002) when blood vessel growth is inadequate and circulation is not properly 
restored due to insufficient angiogenic growth factor production.  
 
Angiogenesis is initiated when pre-existing vasculature becomes permeable due to 
diffusion of angiogenic growth factors. Once growth factors bind to their receptors, 
the endothelial cells (EC) are activated to send signals from the cell's surface to the 
nucleus. This results in degradation of extracellular matrix, cell proliferation and 
migration that ultimately form new blood vessels (Risau 1997). In the pathogenesis of 
pterygium, it has been reported that the abundance of the pterygium angiogenesis 
factors may irritate the limbal basal cells and produce vessel ingrowths to facilitate 
the formation of pterygium (Coroneo 1993). In addition, angiogenesis is controlled by 
the net balance of various pro-angiogenic and anti-angiogenic factors that regulatory 
angiogenic activity (Pepper 1997). This concept is known as ‘‘angiogenic switch,’’ the 
main "on" switches are known as angiogenesis-stimulating growth factors and 
angiogenesis inhibitors are the main "off switches". When angiogenic growth factors 
are produced in excess of angiogenesis inhibitors, the balance is inclined to blood 
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vessel growth while angiogenesis is stopped when the levels of inhibitors exceed the 
level of angiogenic stimulators. Numerous inducers of angiogenesis have been 
identified. The first angiogenic factor was isolated from tumours in the early 1970s 
and more factors were discovered in following years (Folkman and Klagsbrun 1987; 
Folkman and Shing 1992; Folkman 1995).  
 
1.3.4 Transdifferentiation 
Transdifferentiation is a process that permits a cell with a defined phenotype to 
transiently adopt the phenotype of another cell, which is typically a myofibroblast. 
This process can play a positive role in tissue reparation or occurs during pathological 
processes (Sisakhtnezhad and Matin 2012). Granulation tissue fibroblast 
(Myofibroblast) is a cell in differentiation between a fibroblast and a smooth muscle 
cell. Myofibroblasts synthesize extracellular matrix components such as collagen 
types I and III (Gabbiani 2003) and contract by using smooth muscle type 
actin-myosin complex that show abundant expression in the form of alpha-smooth 
muscle actin during normal wound healing or fibrocontractive diseases (Desmouliere, 
Geinoz et al. 1993). After normal wound healing is complete, myofibroblasts 
disappear by apoptosis but in some cases growth of myofibroblasts can persist. 
Continued myofibroblast proliferation and contraction can give rise to fibrotic 
disorders and cancer (Gabbiani 2003; Kellermann, Sobral et al. 2008). 
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Transdifferentiation is considered an important pathological process in pterygium; 
extracellular matrix deposition and connective tissue remodelling are major 
contributing factors (Cameron 1983; Karukonda, Thompson et al. 1995; Coroneo, Di 
Girolamo et al. 1999). Contractile myofibroblasts have previously been characterised 
in pterygium (Kellermann, Sobral et al. 2008).  
 
1.3.5 Extracellular matrix remodelling 
Extracellular matrix (ECM) is defined as connective tissue in extracellular protein 
network. ECM supports tissue structure and can mediate intercellular signal 
transduction (Giancotti and Ruoslahti 1999). Extracellular matrix plays an important 
role in cell growth and differentiation (Lin and Bissell 1993; Meredith, Fazeli et al. 
1993). Collagens are the primary abundant proteins in the ECM that initiate 
fibrillogenesis (Kadler, Hill et al. 2008). When the ECM is deregulated, a variety of 
human diseases can occur. A number of studies demonstrated that fibrogenic 
cytokines like TGFβ and VEGF induce the expression of extracellular matrix proteins, 
mainly collagen deposition (Park, Keller et al. 1993; Leask and Abraham 2004; 
Bataller and Brenner 2005). In addition, MMPs are capable of degrading extracellular 
matrix (ECM) proteins and contribute pathological processes like tissue remodelling, 
angiogenesis and metastasis (Mott and Werb 2004). Extracellular matrix remodelling 
can promote inflammation and restructure the tissue (Stamenkovic 2003). It has 
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been suggested that extracellular matrix remodelling through the actions of MMPs 
and TIMPs are involved the pathogenesis of pterygium (Di Girolamo, Chui et al. 2004). 
In wound healing and fibrotic disease, contracting granulation tissue (myofibroblasts) 
activates the tissue dynamics and synthesizes ECM for rapid wound closure (Guidry 
1992; Desmouliere, Geinoz et al. 1993; Gabbiani 2003). 
 
1.4 Calcium signalling 
Calcium signalling is widely known to play a number of important roles in the 
maintenance and physiological function of cells throughout the body. Our 
understanding of calcium signalling in pterygium is limited and it is of importance to 
address this key gap in our knowledge of this disease. 
 
1.4.1 Intracellular Calcium 
The primary signals received at the cell surface mediate this communication and then 
affect intracellular behaviour via second messenger relay signals from surface 
receptors (Parekh and Penner 1997). Calcium regulates the key cellular physiology 
processes like gene transcription, cell proliferation and metabolism (Berridge 1993). 
Unregulated cellular proliferation, transdifferentiation and angiogenesis are linked to 
Ca2+ signalling activities (Coroneo, Di Girolamo et al. 1999). The concentration of Ca2+ 
in the cytoplasm is typically kept in the range of 10–100nM. The binding of specific 
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receptor proteins on the plasma membrane (PM) results in a rapid increase to the 
500-1000nM range from opening of calcium channels. The endoplasmic reticulum (ER) 
is the main intracellular Ca2+ store/release organelle. The cells can either elevate 
cytosolic Ca2+ by releasing Ca2+ from intracellular store or uptake Ca2+ into the cell 
from extracellular solution by store-operated calcium entry (SOCE) (Parekh and 
Penner 1997). The main signalling mechanism regulating calcium release from the 
endoplasmic reticulum is through phospholipase C pathway (PLC) which catalyses the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the 
intracellular messengers inositol 1,4,5-trisphosphate (InsP3) and diacylglycerol 
(Bootman, Collins et al. 2001). Then InsP3 diffuses into the cell where it binds its 
receptors (InsP3Rs) on the ER/SR to release the calcium.  
 
1.4.2 Receptor mediated pathway 
Although IP3 is the key in opening InsP3Rs, their activation is regulated by the calcium 
concentration at their cytosolic surface (Bootman, Collins et al. 2001). Phospholipase 
C enzymes are activated directly and indirectly by different cell surface receptors 
including growth factors, cytokines and G-protein coupled receptors (GPCR). The 
molecules that activate receptors are ligands. Cells could produce a response 
following stimulation by the extracellular ligand via second messengers. Therefore, 
the ligand-receptor interactions play a fundamental role on cell signalling. Two major 
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receptor-mediated pathways are involved in the formation of Inositol trisphosphate 
(IP3) to release Ca
2+ from ER. G-protein coupled receptors including histaminergic, 
purinergic and muscarinic receptors activate a common pathway by stimulation of 
PLCβ. Alternatively, receptor activation can activate PLCgamma to elevate IP3 and 
mobilize the ER calcium store (Berridge 1993); this is typically associated with growth 
factors such as epidermal growth factor.  
 
G protein coupled receptors (GPCRs) are one of largest superfamily of 
transmembrane receptor proteins in humans and affect a wide variety of cell 
physiological processes and biological functions. G protein coupled receptors form a 
modular system that detects extracellular molecules and transmits the signals over 
the plasma membrane into the intracellular domain and ultimately activates cellular 
responses. GPCRs are also called seven-transmembrane (7TM) domain receptors 
because they pass through the cell membrane seven times. Common structural 
features of GPCRs include a bundle of seven transmembrane alpha helices connected 
by six loops of varying lengths (Palczewski, Kumasaka et al. 2000). 7TM receptors play 
an important role in physiological processes in human which are the key targets for 
many pharmaceuticals drugs. Activation of PLC hydrolyzes the lipid precursor 
phosphatidylinositol 4, 5-bisphosphate (PIP2) to release DAG and IP3. Then IP3 binds 
to its receptor IP3R to mobilize the intracellular calcium (Berridge 1993)(Figure 1.2). 
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Figure 1.2. Two major receptor-mediated pathways involved in the formation of 
Inositol trisphosphate (IP3) to release Ca
2+ from ER. Modified from Calcium signalling, 
Martin D. Bootman 2001.  
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Receptor tyrosine kinases (RTK) are a diverse group of transmembrane proteins that 
act as high-affinity cell surface receptors for many polypeptide growth factors, 
cytokines, hormones and other signalling molecules. Receptor tyrosine kinases are 
involved in a variety of cellular processes, including growth, differentiation and 
angiogenesis. All tyrosine kinase receptors have a similar structure. They each have a 
tyrosine kinase domain that phosphorylates proteins on tyrosine residues, a hormone 
binding domain and a carboxyl terminal segment with multiple tyrosines for 
autophosphorylation. In calcium signalling, RTK stimulates PLCγ which generates IP3  
to activate the calcium store (Berridge 1993). 
 
1.5 Transforming growth factor beta signalling  
The pro-fibrotic factor transforming growth factor beta involves in many biological 
processes including cell growth, differentiation, apoptosis, angiogenesis and fibrosis 
(Roberts, Sporn et al. 1986; Massague 1990; Padgett and Patterson 2001). It is critical 
in tissue repair in human but excessive action of TGFβ also contributes to fibrosis 
disorder (Border and Ruoslahti 1992). TGFβ can induce angiogenesis and stimulates 
fibroblasts to produce collagens (Roberts, Sporn et al. 1986; Connor, Roberts et al. 
1989) and it induces deposition of extracellular matrix and stimulates extracellular 
matrix component including collagens synthesis (Roberts, Sporn et al. 1986; Kagami, 
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Border et al. 1994). Pterygium is regarded as a fibrotic disease and TGFβ is commonly 
implicated in such conditions (Coroneo, Di Girolamo et al. 1999; Verrecchia and 
Mauviel 2007), yet it has been poorly studied in pterygium formation. Pterygium 
demonstrates the accelerated fibroblastic proliferation (Cameron 1983). Pterygial 
fibroblasts indicate a greater growth response as well as more release of growth 
factors compared with normal conjunctival fibroblasts in same conditions (Chen, Tsai 
et al. 1994; Kria, Ohira et al. 1998). It is reported that the fibrogenic stimuli may 
induce the transdifferentiation from fibroblasts to myofibroblasts which were also 
found in fibrovascular tissues of primary and recurrent pterygium (Dushku and Reid 
1994; Kalluri and Neilson 2003). Transforming growth factorβ is a multifunctional 
protein, which belongs to TGFβ super family that is known to regulate cell growth, 
differentiation, apoptosis and immune functions (Border and Ruoslahti 1992). The 
TGFβ superfamily is comprised of a large group of proteins, including inhibitin, 
activin, anti-mullerian hormone, bone morphogenetic protein (BMPs) and growth 
differentiation factors (GDFs). TGFβ receptors are serine/threonine-protein kinase 
receptors and there are three different types of TGFβ receptors, TGFβ receptor 1, 
TGFβ receptor 2 and TGFβ receptor 3; these can be distinguished by their structural 
and functional properties (Cohen 1997; Massague 2000). Three isoforms namely 
TGFβ1, TGFβ2 and TGFβ3, they functionally interact with each other (Border and 
Ruoslahti 1992). Recent study has found that antagonists can block TGFβ signalling, 
which can inhibit the effects of fibrosis (Liu, Hu et al. 2006). The TGFβ response is cell 
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type specific and subject to activation of various signal transduction pathways (Figure 
1.3). The Smad signalling pathway is the most studied mode of signal transduction in 
response to TGF- (Derynck, Zhang et al. 1998). Smad proteins are distinguished by 
three functional classes: receptor-regulated Smad (Smads 2 and 3); co-Smad (Smad 4) 
and inhibitor Smad (Smad 7). Transforming growth factorβ ligands can specifically 
bind to and activate serine/threonine kinase cell-surface receptor (type II receptor) 
and activate various responses. Type II receptor is able to recruit and phosphorylates 
a type I receptor. Type I receptor phosphorylates receptor-regulated Smad2/3, which 
engages with Smad4 to form a complex to translocate to the nucleus to stimulate 
transcriptional regulation (Wu, Hu et al. 2001). Nuclear cofactors that associate with 
the Smad complex can regulate the transcription of target genes (Shi, Wang et al. 
1998). Smad7 can negatively regulate TGFβ signalling by competing with R-Smads 
and consequently regulate gene transcription (Landström, Heldin et al. 2000).  
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Figure 1.3. TGFβ signalling/Smad pathway. The current model of induction of 
signalling responses by TGF--related factors is a linear signalling pathway from the 
type II to the type I receptor kinase to Smad activation, resulting in ligand-induced 
transcription. 
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1.6 Genetic factors, viral infections and pterygium 
UV irradiation leads to DNA damage which follows with gene mutation and genomic 
instability. Although the relation between pterygium and genetic factors are unclear 
but a family history is frequently reported. Elevation of P53 expression alteration, loss 
of heterozygosity (LOH) and genetic polymorphism of hOGG1 may be the co-factors to 
pterygium (Detorakis, Drakonaki et al. 2000; Kau, Tsai et al. 2004; Rodrigues, Arruda et 
al. 2008). The Ku70 promoter T-991C polymorphism is also a potential genetic marker 
for pterygium susceptibility (Tsai, Bau et al. 2007). It was reported that VEGF-460C 
polymorphism in female patients increases the risk of pterygium (Tsai, Chiang et al. 
2008).  
 
In addition, a number of studies identified oncogenic viruses in pterygia. Human 
papilloma virus (HPV) and herpes simplex virus (HSV) were detected in pterygium in 
several studies (Detorakis, Drakonaki et al. 2000). It has been reported HPV 16/18 was 
detected in 24% of the pterygium tissues but not in normal conjunctival tissues and 
48.3% of HPV 16/18 DNA-positive pterygium tissues expressed HPV 16/18 E6 
oncoprotein (Tsai, Chang et al. 2009). Epstein-Barr virus (EBV) was also detected in 
10% of primary pterygial patients (Otlu, Emre et al. 2009).Therefore, viral infections 
may also contribute to the development of pterygium.   
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1.7 Aim  
 
Pterygium is a highly vascular fibrotic disease. It is therefore important to understand 
the role the vascular system plays in the physiological behaviour of cell populations 
within pterygia and the factors that can promote fibrotic change. The current project 
involved studies aimed to address these issues. The main aims of the project were: 
 To determine receptor mediated calcium signalling responses in the presence 
and absence of serum, which mimic a rich and poor blood supply.  
 To determine the functional importance of calcium signalling in 
pterygial-derived fibroblasts 
 To determine the ability of TGFbeta to induce fibrotic responses in 
pterygial-derived fibroblasts 
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CHAPTER 2 
Materials and methods 
All reagents were purchased from Sigma (Sigma, Poole, Dorset) unless otherwise 
stated. 
2.1 Tissue culture 
2.1.1 Isolation and culture of pterygial-derived fibroblasts 
The pterygial tissues were obtained from patients at the Norfolk and Norwich 
University Hospital and Harbin Ophthalmological Hospital in China after surgery. The 
conjunctiva tissues were kindly provided by Norfolk and Norwich University Hospital. 
The use of human tissue in this study was in accordance of the Declaration of Helsinki. 
For experimental purposes cells were employed between passage 3 and 9. In some 
cases conjunctiva and pterygium were fixed and analysed using 
immunohistochemistry. In the majority of cases, pterygial samples were placed into 
an Eppendorf tube which contained Eagle’s minimum essential medium (EMEM; 
Sigma, Poole, Dorset, U.K.) supplemented with 10% foetal calf serum (FCS; Gibco, 
Paisley) and 50 mg/l gentamicin. The tissue was dissected into ~5mm2 pieces and 
transferred from the tube to a 35mm round tissue culture dish with 1.5ml fresh 
medium. Under the microscope the tissue was secured to the tissue culture dish 
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using entomological pins (D1, Watkins and Doncaster Ltd, Cranbook Kent, U.K)(figure 
2.1A). The tissues were cultured in an incubator (maintained at 35 0 C in a 5% CO2 
atmosphere). Medium was replaced every 3-4 days. Viable preparations 
demonstrated pterygial cell outgrowth from the tissue onto culture dishes, these 
primary cultures demonstrated a mixed population of epithelial cells and fibroblasts 
(Figure 2.1B). Once a sufficient number of cells had grown onto the culture dish, the 
tissue was transferred to a new dish and the medium was removed from cells. Then 
the cells were washed with Dulbecco’s Phosphate Buffered Saline (DPBS) and then 
the pterygial cultures were trypsined with 0.02% (w/v) ethlenediaminetetraacetic 
acid (EDTA) in Hank’s balanced saline solution for 2 to 5 minutes in incubator to 
detach the cells from the bottom but the remaining cells were released by tapping 
the base of the dish. The cell number was counted under the microscope with a 
haemocytometer. Afterwards, the cell suspension was centrifuged for 5 minutes at 
1000rpm and the supernatant was removed. Cells were re-suspended in the new 
culture medium and plated either to culture dishes, flasks or coverslips and 
maintained at 35 0 C in 5% CO2 atmosphere. Medium was changed every 2-3 days and 
were passaged to the new dishes. Finally, cultures contained pure population of 
fibroblasts (Figure 2.1D) that were identified immunocytochemically. The pterygial 
fibroblasts were seeded in the 96 well plates for MTS, calcium imaging, tissue culture 
dishes for immunocytochemistry, RT-PCR, Western blot, microarray, patch assay and 
scratch assay. Part of pterygial tissues were kept in 4% Formaldehyde and stored  
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Figure 2.1: Morphologic characterization of pterygial cell outgrowth. (A) Native 
pterygial tissue pinned out onto a 35mm culture dish; (B) phase micrograph shows 
the cells outgrow from edge of the pterygial tissue (arrowed). (C) mixed populations 
of pterygial-derived (epithelial cells and fibroblasts) cells; (D) Cell cultures of 
passaged cells exhibiting a consistent fibroblast morphology. The field of view 
represents 4.2 x 3 mm (A), 2.1 x 1.5 mm (B) and 800 x 571 m (C&D). 
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at 4°C for immunohistochemistry experiments.    
2.1.2 Storing and recovering the cells  
Cells were stored for future studies in case of cell contamination. Therefore 
cryopreservation was employed to store the cell lines. Following trypsinisation cells 
were resuspended in freezing medium (1ml 5-10% (v/v) DMSO) (Sigma, Poole, UK) to 
create a cell suspension of 1x106 cells/ml and 1ml cell suspension was transferred to 
cryogenic vials (Corning, NY, USA). Vials were placed immediately to -20°C for one 
hour, followed by -80°C overnight before long term storage in liquid nitrogen (-197°C). 
When recovering the cells, medium was pre-warmed and cryovials were removed 
from liquid nitrogen and immediately placed in a 37°C water bath to quickly melt the 
freezing medium. The suspension was pipetted out into a flask with 10% FCS EMEM 
and placed in incubator at 35°C in a 5% CO2 atmosphere. The medium was changed 
every 2-3 days until sufficient populations were established to permit experiments to 
take place.  
 
2.1.4 Photomicroscopy 
Phase contrast images of native and cultured pterygial cells were taken using a Nikon 
TE200 Eclipse Microscope ( Nikon industries, Tokyo Japan) fitted with a Nikon coolpix 
950 digital camera and MDC lens (Nikon industries, Tokyo Japan).  
  
 
25 
 
2.2 Histology  
2.2.1 Paraffin embedding and slicing the sample  
Fresh human conjunctival and pterygial tissue (typically thickness less than 0.5 cm) 
were stored in fixative solution (4% formaldehyde) to maintain the original 
morphology of cells. The tissue was dehydrated through transfer from low 
concentration to high concentrations of ethanol (30%, 50%, 70%, 90%, and 100% for 
30 minutes respectively). Tissues were then placed in a half ethanol/half xylene 
solution for 30 minutes then another half an hour in solely xylene to make the tissue 
transparent. Subsequently, specimens were placed in 50% xylene and 50% paraffin 
solution at 60℃ for one hour and then heated in pure paraffin for another hour. The 
samples were cooled in the sink with water and stored in the fridge. Using a 
microtome, the fixed paraffin embedded specimens were sliced into 6µM sections 
and placed on glass slides. 
 
2.2.2 Hematoxylin and eosin stain (H&E stain)  
The specimen sections were placed in xylene for 5 minutes twice and then they were 
hydrated through transfer from 95% alcohol to 30% every 3 minutes then placed into 
distilled water for 1 minute. The nuclei were stained with the alum haematoxylin for 10 
minutes followed by rinsing under running tap water for several seconds to remove the 
over-staining. Subsequently, they were differentiated with 1% acid alcohol and rinsed in 
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running tap water for a further 10 seconds. The specimens were counterstained with 
xanthene dye eosin for 3 minutes and rinsed in running tap water to remove the 
over-staining. In this process, cytoplasm, collagen and keratin were stained red. 
Afterwards, the samples were dehydrated with 30% to 90% alcohol 1 minute 
respectively and 2 minutes in 95%, twice 5 minutes in xylene. Then coverslips were 
placed above the samples using hydromount solution (National Diagnostic, Hessle Hull, 
U.K.). 
 
2.2.3 Immunohistochemistry 
The tissues were sectioned into 6μm thick sections and put onto slides overnight. The 
samples were hydrated and the glass slides were placed in plastic square dishes with 
PBS poured into the corner. PBS was slowly poured into dishes to avoid washing the 
samples away from the slides. Then the square dish was placed on a shaker for 10 
minutes and the washing process was repeated three more times. The slides were 
picked from PBS and dried carefully with tissue. 50μl of blocking solution (5% Goat 
serum, 0.2% Triton X-100 in PBS) was then added to each sample at room 
temperature for 90 minutes; a plastic coverslip was placed over each sample to 
ensure even distribution of solution and prevent evaporation. After that, plastic 
coverslips were removed with forceps. 50μl of primary antibody (anti-vimentin 
mouse monoclonal antibody; anti-cytokeratin mouse monoclonal antibody; 
anti-aSMA mouse monoclonal antibody) diluted 1:100 in blocking solution was then 
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added to each specimen and plastic slips were placed back. The samples were 
incubated with first antibody overnight at 4°C.  
 
Samples were then washed for 5 minutes with 0.02% BSA-0.05% IGEPAL in PBS. The 
samples were then incubated in ALEXA 488-conjugated secondary antibodies 
(Molecular Probes, Leiden, The Netherlands) for 2 hours at room temperature. After 
washing with PBS, 1:100 DAPI-phalloidin (Invitrogen, Eugene, Oregon, USA) diluted in 
PBS was added to tissues for 10 minutes in the dark. DAPI was used to dye the cell 
nuclei and the actin cytoskeleton was stained with phalloidin conjugated to Texas 
Red. After final washes, the specimens were mounted on a glass microscope slide by 
inverting the coverslip onto a drop of hydromount (National Diagnostis, Hessle Hull, 
U.K.). Slides were left to dry for 1 hour at room temperature and stored in the fridge 
in the dark until imaged. The samples were viewed with a Zeiss Axiovert fluorescent 
microscope (Melville, NY, U.S.A) and Zeiss Axiovision software.  
 
2.2.4 Immunocytochemistry   
Pterygial-derived fibroblasts were seeded at a density of 5000 cells/100l on a square 
sterile coverslip housed in a tissue culture dish before the day of the experiment. 
After the cells adhered to the coverslip, 2ml of EMEM supplemented with 10 % FCS 
was added to each dish and culture dishes maintained at 35°C in a 5% CO2 
atmosphere. The medium was changed to serum-free for 24 hours later. For 
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phenotypic characterisation cells were fixed at this time point using 4% formaldehyde 
in phosphate buffered solution (PBS) at RT for 30 minutes. In some cases, TGFβ was 
added and cultures were maintained up to 4 hours in experimental conditions before 
fixation. Preparations were then washed twice for 5 minutes with PBS. Cells were 
then treated with 0.5% Triton X-100 in PBS for 30 minutes followed by three washes 
with 0.02% BSA-0.05% IGEPAL in PBS. 40μl normal goat serum (NGS) made up in 1% 
BSA PBS at 1:50 dilutions was added to bind non specific sites. This was followed by 
addition of 40µl primary antibody (anti-vimentin mouse monoclonal antibody; 
anti-cytokeratin mouse monoclonal antibody; anti-aSMA mouse monoclonal antibody; 
anti-smad2/3 mouse monoclonal antibody), which were diluted 1:100 in 1% BSA PBS 
and applied overnight at 4°C or incubated at 37°C for 1 hour. Preparations were then 
washed three times with 0.02% BSA-0.05% octylphenoxy polyethoxyethanol IGEPAL 
in PBS. Following washes, the cells were incubated in appropriate ALEXA 
488-conjugated secondary antibodies (Molecular Probes, Leiden, The Netherlands) 
for 1 hour at room temperature in the dark.  After washing three times with PBS 
alone, 1:100 diluted DAPI-phalloidin (invitrogen, Eugene, Oregon, USA) in PBS was 
added to tissues for 10 minutes in the dark. DAPI was used to stain the cell nuclei and 
the actin cytoskeleton was staining by phalloidin conjugated to Texas Red. After final 
3 washes, the specimens were mounted on microscope slides using Hydromount 
solution (National diagnostis, Hessle Hull, U.K.). The samples were viewed with a 
Zeiss Axiovert fluorescence microscope (Melville, NY, U.S.A) and Zeiss axiovision 
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software. ImageJ software was applied to analyse the captured images when 
appropriate.   
 
2.2.4.1 Quantification of Smad2/3 nuclear accumulation 
Smad2/3 nuclear accumulation was quantified using ImageJ software. Triple or dual 
colour immunocytochemistry images were analyzed using Image J analysis software. 
DAPI staining defined the nucleus and the nuclear boundary for each cell was then 
drawn and a pre-defined area in the cytoplasm surrounding the nucleus was 
identified. Thus a nuclear and cytoplasmic compartment was identified. The 
fluorescent SMAD intensity was averaged over the measured area for each cell 
analysed and the difference in values was calculated. 
 
2.3 MTS assay  
Pterygial fibroblasts in 200ul (EMEM supplemented with 10% FCS) medium were 
seeded in each well of a 96-well tissue culture plate and maintained at 35°C in 5% 
CO2 incubator. Then the medium was replaced with non-supplemented EMEM and 
cultured overnight. The cells were then placed in experimental conditions for 24 or 
48 hours. Pterygial fibroblast number was determined using the CellTiter 96 Aqueous 
Non-Radioactive Cell Proliferation Assay (Promega, Southampton, UK). Following the 
experimental duration, medium is removed from each well and replaced with, 100μl 
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MTS solution and incubated at 35°C in a 5% CO2 atmosphere for one hour. The 
amount of coloured product was directly proportional to the number of cells. The 
plate was read at 490 nm using a BMG labtech FluoStar Plate reader (Aylesbury Bucks, 
USA). 
 
2.4 Scratch wound assay  
Pterygial fibroblasts were seeded on a 35mm tissue culture dish at a density of 5000 
/200 µl of 5% FCS-EMEM and allowed to establish over a 48 hours period, such that a 
distinct patch of cells (~1cm in diameter) was observed. The medium was then 
replaced with non-supplemented EMEM and cultured for a further 24 hours. At this 
time-point a scratch was made through the middle of the confluent sheet using a 
plastic pipette tip. Indentations within the wound area were made to establish points 
of reference. The cells were then exposed to experimental conditions and maintained 
for 24 hours with the medium being changed every 2 days. Images were captured 
and the movement determined using image analysis software (Image J). 
 
2.5 Calcium signalling  
Pterygial fibroblasts were seeded in each well of a transparent 96-well microtitre 
plate at a density of 5000 cells/200µl of 10% FCS-EMEM and allowed to establish. 
Medium was removed and replaced with serum free EMEM or EMEM supplemented 
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with 10% serum for a 48 hour period. The cells were then loaded with 5µM Fura 
2-acetoxymethylester (Fura 2-AM) in EMEM for 40 minutes (Figure 2.2A). Following 
this period, the medium in each well was changed to Standard Ringer solution (AAH; 
5mM KCl, 5mM NaHCO3, 5mM glucose, 20mM HEPES, 130mM NaCl, 0.5mM MgCl2, 
1mM CaCl2, pH 7.25) or calcium free Ringer solution (5mM KCl, 5mM NaHCO3, 5mM 
glucose, 20mM HEPES, 130mM NaCl, 0.5mM MgCl2, 1mM EGTA, pH 7.25) (Rhodes, 
Russell et al. 2009). The plate was placed in a FLUOstar Omega multidetection 
microplate reader (BMG LABTECH Ltd, Offenburg, Germany), which was maintained 
at 35°C (Figure 2.2B). Fura 2 was excited alternately with 340 and 380nm 
wavelengths with emission detected at 520nm. Calcium levels were initially 
determined by the ratio of FURA-2 signal at 340nm/signal at 380nm. The ratio value 
at the onset of the experiment (t=0) served as a reference signal (F0); all subsequent 
readings were established as an F1/F0 ratio. Peak responses following stimulation 
were determined using the MAX feature on Excel (Microsoft). 
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Figure2.2. A: The principle of FURA2 entry and entrapment within cells. B: Top view 
of reagent box in BMG labtech FluoStar Plate reader. 
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2.6 Patch growth assay 
The patch assay technique was employed on pterygial fibroblasts to investigate the 
cell ability in migration and proliferation (Figure 2.3). Pterygial fibroblasts were 
seeded on a 35mm tissue culture dish at 5000 cells in 200 µl of 10% FCS-EMEM and 
allowed to establish over a 48 hour period, such that a distinct patch of cells (~1cm in 
diameter) was observed. Pterygial fibroblasts were placed in experimental conditions 
for 48 hours; conditions were 10% FCS EMEM ± 1µM thapsigargin. At end-point, cells 
were washed with PBS and stained with Coomassie blue (Merck, Germany) for 1 hour 
to enable the patches to be visualized and measured. The dye was removed and the 
cells were washed with PBS several times to remove excess dye. Images of individual 
patches were captured on a CCD camera using Genesnap software (Synoptics, 
Cambridge, UK). Cell coverage was determined using Image J software. To provide an 
estimate of total cell number, the Coomassie blue dye within the cells was extracted 
by removal of PBS and addition of 1ml 70% ethanol. 100µl samples of each dish were 
transferred to a 96 well plate. The level of dye content was assessed by measuring 
absorbance at 550nm using a BMG labtech FluoStar Plate reader (Aylesbury Bucks, 
USA). 
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5000 Pterygial fibroblasts were 
seeded in tissue culture dishes
Serum free overnight
Cells were fixed in 4% 
formaldehyde at t=0
Treated experimental 
conditions
Patches stained with coomassie
blue and area quantified
Dye content measure the 
absorbace at 550nm 
Dye extracted using 70% ethanol and 
absorbance measured at 550nm
 
 
     Figure 2.3. Diagram of patch assay. 
 
 
 
 
 
  
 
35 
 
2.7 RT-PCR 
2.7.1 RNA Extraction 
Total RNA was isolated from cultured pterygial fibroblasts using RNeasy Mini Kit 
column based method according to the manufacturer’s instructions (Qiagen Ltd, 
Crawley, UK). Cell-culture medium was aspirated and 350µl of buffer RLT was added 
to the cell-culture dish. Cells were scraped off the dish using a cell scraper. Cell lysate 
was collected into an Eppendorf tube. 350µl of 70% ethanol was added to the 
homogenized lysate and mixed by pipetting with a gauge needle to a RNase free 
syringe without centrifuge. The samples were spun at 13000 rpm for 3 minutes and 
supernatant was collected. And then sample was put into an RNeasy mini column and 
placed in a 2 ml collection tube; Centrifuged for 30s >=8000xg. Discarded the 
flow-through and 700µl buffer RW1 was added to the RNeasy column, centrifuged for 
60s and discarded the flow through. The Rneasy column was transferred into a new 
collection tube and 500 µl Buffer RPE containing ethanol was added. Another 
centrifuge for 15s and the flow-through was discarded. 500µl Buffer RPE was added 
to the Rneasy column and then centrifuged it for 2 minutes to dry the Rneasy 
silica-gel membrane. Then transferred the Rneasy column in new 1.5ml collection 
tube and 50µl Rneasy- free water was added onto the Rneasy silica-gel membrane. It 
was either used immediately for cDNA synthesis or stored short term at -80℃. The 
concentration of RNA was measured by using Nanodrop ND-1000 spectrophotometer 
(NanoDrop Technologies, USA). 
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2.7.2 Synthesis of cDNA 
1000ng of total RNA was used as a template for first strand cDNA synthesis. 1µl 
random primers and 1µl 10mM dNTP mix were added into each tube. Then 1000ng of 
total RNA and double diluted water in 12µl total amount were added to each tube, 
and then it was spun down at maximum 13000 rpm for 15s. The thermocycler DNA 
engine (MJ Research, Inc, USA) was applied to heat samples to 65°C for 5 minutes and 
followed by quick chill on ice. The contents of the tube was collected by briefly 
centrifuging and then added 4µl 5x First-Strand Buffer, 2µl 0.1 M DTT and 1µl 
RNaseOUT Recombinant Ribonuclease Inhibitor (40 units/µl) to each tube. The tube 
was incubated at 25°C for 10 minutes and 42°C for 2 minutes. Subsequently, 1µl 
superscript II was quickly added into each tube. This was followed by incubating the 
tube at 42°C for 15 minutes and 70°C for 15 minutes to stop the reaction. The cDNA 
product was either stored at -20°C or used straight away for PCR. 
 
2.7.3 QRT-Polymerase chain reaction 
Primer oligonucleotide sequences specific for the genes examined are shown in 
(Table 2.1). The level of product was determined by SYBR green (Finnzymes, 
Espoo, Finland), it binds exclusively to double-stranded DNA which leads to a 
fluorescence emission. Therefore, the product is proportional to fluorescence. 
Subsequently, SYBR green/ primer mix was made up as follows: SYBR green 
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equate to half the total mix; forward primer equate to 1/10 of SYBR green; 
reverse primer equate to 1/10 of SYBR green; the remainder of the mix volume 
was made with RNase free water. 45µl mix and 5 µl appropriate sample 
cDNA/calibration were added to 0.5ml Eppendorf tubes. Serial dilutions of cDNA 
known to express the gene of interest were prepared to permit relative levels 
between test samples to be determined. QRT-PCR was performed with the 
following program: step 1, initial denaturation for 94°C for 4 minutes; step 2, 
denaturation for 94°C for 20 seconds; step 3, annealing at 55°C for 30 seconds; 
step 4, extension at 72°C 20 seconds; step 5, cutoff for 10 seconds at 80°C to 
denature potential primer dimers, followed by fluorescent dye measurement. 
Steps 2 to 5 were repeated for 35 cycles. In addition, melting curve analysis was 
performed to determine the quality of the product.  
 
 
 
Table 2.1. Primers employed for QRT-PCR 
 
Gene of 
Interest 
Forward primer (5’-3’)  Reverse primer (5’-3’)   Reference 
Alpha SMA 
 
GAPDH 
CCCAGCCAAGCACTGTCA 
 
ACCACAGTCCATGCCATCAC 
TCCAGAGTCCAGCACGATG 
 
TCCACCACCCTGTTGCTGTA 
Lee and Joo, 1999 
 
Yang et al., 1996 
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2.8 Western blot analysis 
2.8.1 Protein extraction 
Cells were incubated in serum-free medium overnight and then changed to the 
experimental conditions. Mammalian protein extraction reagent (M-PER; 
Thermoscientific, Rockford, USA) was supplemented with 10l/ml protease inhibitors 
from the Halt TM phosphatase inhibitor kit (Thermo Scientific, Rockford, USA). 
Additionally, 10µl/ml of 0.5M ethylenediaminetetraacetic acid (EDTA) was added to 
dishes to act as a metalloproteinase inhibitor. Cells were rinsed with 500µl ice-cold 
PBS. Afterward, 350µl of M-PER and inhibitors were added to each sample dish. The 
dish was placed on a shaker for 5 minutes and then the cells were scraped from the 
base of the dishes using a pre-cleaned cell scraper. Lysates were pre-cleared by 
centrifuging at 14000 rpm to pellet the cell debris. The supernatant was transferred 
to 0.5ml Eppendorf tubes and stored at -20 or -80°C prior to use.  
 
2.8.2 BCA protein assay 
The protein content was assayed by Bicinchoninic acid assay (BCA) so that equal 
amounts of protein per sample were loaded onto SDS-Page gels for electrophoresis 
and transfer to PVDF (polyvinylidene difluoride) membrane. The BCA assay combines 
two reactions. Primarily, the peptide bonds in protein reduce Cu2+ ions from the 
cupric sulfate to Cu+. The amount of Cu2+ reduced is proportional to the amount of 
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protein in the alkaline medium. Secondly, bicinchoninic acid chelates with each Cu+ 
ion and a purple-colored reaction mixture was formed that strongly absorbs light at 
562 nm. Protein standards were prepared by diluting 2mg/ml bovine serum albumin 
(BSA) over a working range of 25-1000µg/ml in lysis buffer stock solution. 40 µl of 
ddH2O was added to each well of a 96 well plate. 10µl of samples, standards or 
blanks were pipetted into separate wells in duplicates. The BCA working reagents 
(WR) contained 50 parts of the reagent A for 1 part of reagent B and 200µl was added 
to each well. The plate was mixed well on the plate shaker for 30 seconds then 
covered it and incubated at 37°C for 1 hr.  Plates were cooled to room temperature 
and the absorbance was read at 550nm on a multi-well plate reader (Fluostar Omega, 
BMA Labtech). The results were analyzed in Microsoft Excel. 
 
2.8.3 SDS-PAGE gel electrophoresis and protein transfer 
Each sample required 7µl of loading buffer containing 12.5% beta-Mercaptoethanol. 
Each tested protein sample consists of 28µl protein and 7µl loading buffer in a 0.5ml 
Eppendorf tube. The samples were centrifuged at 13000 rpm at 4°C for 1-2 minutes 
and heated for 5 minutes at 100°C using the MJ research gene engine (Alpha UnitTM 
Block Assembly for PTC DNA EngineTM System) (MJ Research, Inc. Watertown, USA). 
Then the samples and markers were loaded with long-nosed pipette tips to the SDS 
gels. The gels were run at 0.06 AMPs 60 minutes. Polyvinylidene fluoride (PVDF) 
membrane was activated in methanol for 30s. And then the gels, blotting paper and 
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PVDF membrane were equilibrated for 25-30 minutes at RT in transfer buffer. 
Afterwards, the proteins were transferred from the gel to the PVDF membrane in the 
Bio-Rad power Pac setting the volts at 15 V and AMPs at 0.3A per gel for 35 minutes. 
 
2.8.4 Immunoblotting and development 
After transfer, PBS-T blocking solution was made up in 0.5% Tween-20 (Fisher 
Scientific, New Jersey, USA) in PBS with 5% fat-reduced milk powder (Marvel). The 
membrane was placed in a square petri-dish filled with PBS-T and positioned on a 
shaker for one hour at RT to block the non-specific sites on the membrane. 
Subsequently, the membrane was incubated with the primary antibody (Abcam, 
Cambridge, U.K.) diluted 1:1000 in Marvel PBS-T overnight at 4°C. Secondary 
antibody used a Horse Radish Peroxidase (HRP) (Cell Signalling Technology) at a 
concentration of 1:1000 in Marvel PBS-T and additionally 0.5µl other secondary 
component for the Dual Vue makers (CPK 1070) was added to the solution. They 
were applied for 1 hour and bands were detected using ECL plus Western blotting 
detection reagents (GE Healthcare USA, Piscataway, NJ) according to manufacturer’s 
instructions. The photographic film was developed in the dark room then it can be 
scanned and measured using imagineJ analysis software.  
 
 
  
 
41 
 
2.9 Proteome Profiler™ Array 
Pterygial fibroblasts were maintained in experimental conditions for 48 hours. The 
bathing medium was sampled and analysed using a commercially available proteome 
profiler array. This permits evaluation of a number of targets established through 
capture antibodies spotted in duplicate on nitrocellulose membranes. A layout of the 
membrane and a list of angiogenic factors assessed are provided in (Table 2.2). The 
blocking buffer was added to each well of a 4-Well Multi-dish containing a proteome 
profiler membrane. Samples are diluted and mixed with a cocktail of biotinylated 
detection antibodies then incubated with the Human Angiogenesis Array overnight at 
2-8 °C on a rocking platform shaker. Any protein/detection antibody complex present 
was bound by its cognate immobilized capture antibody on the membrane. Each 
membrane was washed three times with 1X Wash Buffer for 3 X 10 minutes on a 
rocking platform shaker to remove unbound material. The membrane was incubated 
with diluted streptavidin-HRP in the 4-Well Multi-dish for 30 minutes at room 
temperature on a rocking platform shaker. After another three washes, 1 ml chemi 
Reagent Mix was added onto each membrane. Finally, ECL plus reagents (GE 
Healthcare USA, Piscataway, NJ) was used according to manufacturer’s instructions. 
The photographic film was developed in the dark room. Light was produced at each 
spot in proportion to the amount of analyte bound.  
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Table 2.2. Coordinate reference for analyte identification. 
Coordinate Target/Control Alternate Nomenclature Coordinate Target/Control Alternate Nomenclature 
A1,A2 Positive Control Control (+) C15,C16 IL-1β Interleukin-1 beta 
A5,A6 Activin A ACVR1 C17,C18 IL-8 Interleukin-8 
A7,A8 ADAMTS-1  C19,C20 LAP(TGF β1)  
A9,A10 Angiogenin ANG C21,C22 Leptin LEP 
A11,A12 Angiopoietin-1 ANG-1 C23,C24 MCP-1 CCL2 
A13,A14 Angiopoietin-2 ANG-2 D1,D2 MIP-1α CCL3 
A15,A16 Angiostatin PLG D3,D4 MMP-8  
A17,A18 Amphiregulin AREG D5,D6 MMP-9  
A19,A20 Artemin ARTN D7,D8 NRG1- β1 HRG1- β1 
A23,A24 Positive Control Control (+) D9,D10 Pentraxin 3 (PTX3) TSG-14 
B1,B2 Coagulation Factor III TF D11,D12 PD-ECGF TYMP 
B3,B4 CXCL16 Chemokine ligand 16 D13,D14 PDGF-AA  
B5,B6 DPPIV DPP4 D15,D16 PDGF-AB/BB  
B7,B8 EGF  D17,D18 Persephin PSPN 
B9,B10 EG-VEGF  D19,D20 PIGF  
B11,B12 Endoglin ENG/CD105 D21,D22 Prolactin PRL 
B13,B14 Endostatin COL18A1 E1,E2 Serpin B5 Maspin 
B15,B16 Endothelin-1 ET-1/EDN1 E3,E4 Serpin E1 PAI-1 
B17,B18 FGF acidic FGF-1 E5,E6 Serpin F1 PEDF 
B19,B20 FGF basic FGF-2 E7,E8 TIMP-1  
B21,B22 FGF-4  E9,E10 TIMP-4  
B23,B24 FGF-7  E11,E12 Thrombospondin-1 TSP-1 
C1,C2 GDNF  E13,E14 Thrombospondin-2 TSP-2 
C3,C4 GM-CSF  E15,E16 uPA PLAU 
C5,C6 HB-EGF Heparin bing EGF E17,E18 Vasohibin VASH 
C7,C8 HGF  E19,E20 VEGF  
C9,C10 IGFBP-1  E21,E22 VEGF-C  
C11,C12 IGFBP-2  F1,F2 Positive Control Control (+) 
C13,C14 IGFBP-3  F23,F24 Negative Control Control (-) 
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2.9.1 Data analysis 
The positive signals on the developed film were identified. A transparent overlay was 
placed on the array images and aligned with the three pairs of positive control spots 
in the corners of each array. Profiles were created by quantifying the mean spot pixel 
densities. Array signals from scanned X-ray film images were analyzed by Image J 
analysis software. 
 
2.10 Illumina Gene Array 
Routinely cultured pterygial fibroblasts maintained in EMEM were treated with either 
TGFβ2 at 1ng/ml or 10% serum in EMEM for 24 hour. Then total RNA was isolated 
from cultured pterygial fibroblasts using RNeasy Mini Kit column based method 
according to manufacturer’s instructions. The Illumina microarray platform was 
selected to provide a comprehensive view of multiplex gene expression and 
genotyping under the different conditions. A Human-HT12 Expression BeadChip 
(Illumina, San Diego, CA. BD-25-113) array platform was employed. RNA samples 
were prepared as described section 2.7 and shipped to a commercial microarray 
facility and quality assessed using Nanodrop and an Agilent RNA pico labchip; only 
samples with an RNA integrity number (RIN) ≥ 9 were used in the study. Each Illumina 
BeadChip allows simultaneous analysis of 12 arrays, each with > 48,000 probes 
derived from human genes in the National Centre for Biotechnology Information 
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(NCBI). Oligonucleotide spots were synthesized onto the silica beads. The Bead chips 
were imaged using Illumina’s Bead BeadStation scanner. The Bioconductor package 
(http://www.bioconductor.org) in R (http://www.r-project.org) was used to analyze 
the Illumina microarray (BeadArray) unnormalised probe profile data (Lim, Chung et 
al. 2008). Firstly, the data from different chips were loaded into R to be background 
corrected, quantile normalised and variance stabilised. Gross changes in gene 
expression were computed by a log fold change (lfc). For finding the meaningful 
biologically role of the genes, a p value threshold criteria was utilized for each gene 
using an extension of the empirical Bayes moderated t-statistic known as TREAT 
(McCarthy and Smyth 2009). Differentially expressed genes that had a fold change 
threshold of 2.0 (1 log fold change) and a p value of <0.05 were identified as significant. 
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CHAPTER 3 
Serum deprivation can suppress calcium cell signalling in pterygial derived 
fibroblasts 
 
3.1 Introduction 
Pterygium show higher vasculature and a greater growth response relative to normal 
conjunctiva (Chen, Tsai et al. 1994; Kria, Ohira et al. 1998)(Aspiotis, Tsanou et al. 2007). 
Abundance of serum is possible to support the pterygial fibroblasts by supplying the 
tissue with oxygen and growth factors to the cells survival and proliferation. An 
investigation of serum supplement was used in pterygial derived cells and showed that 
cells cultured in the presence of serum are more irregular and grew faster than cells 
cultured in serum free medium (Di Girolamo, Tedla et al. 1999). A rich blood supply can 
therefore promote the rate of pterygium formation and understanding how this source 
of nutrients, survival factors and oxygen facilitates these changes is an important aspect 
of pterygia biology that requires further study. To mimic a rich and poor blood supply 
cells were maintained in either serum rich or serum depleted medium and comparisons 
made. In particular differences in calcium signalling, gene expression patterns and the 
regulation of angiogenic factors were assessed. 
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Calcium is an essential element in maintaining normal physiological function. It is 
considered a versatile second messenger that is able to regulate many cellular physiology 
processes (Berridge 1993). Many of the physiological features of pterygium such as 
persistent cellular proliferation, transdifferentiation and angiogenesis could be attributed 
to Ca2+ signalling activities (Coroneo, Di Girolamo et al. 1999). However, the fluctuation of 
the calcium will impact physiological function directly or even leading to many kinds of 
disease. Therefore, calcium has long been researched because of its key importance in 
human disease. Pterygial tissue is characterized by extensive cellular proliferation, 
transdifferentiation and angiogenesis which are linked to Ca2+ signalling activities 
(Coroneo, Di Girolamo et al. 1999). G-protein coupled receptors including histaminergic, 
purinergic and muscarinic receptors release calcium from intracellular stores through 
activation of PLCβ. Alternatively, epidermal growth factor (EGF) is a tyrosine kinase-linked 
receptor that can utilise PLCgamma to elevate IP3 and mobilise the ER calcium store 
(Berridge 1993). The regulation of calcium signalling through recruitment of the 
endoplasmic reticulum store has not been well studied in pterygial cells. The present 
study therefore aimed to understand the effects of serum deprivation on calcium cell 
signalling events and the functional role of calcium signalling per se in pterygial-derived 
fibroblasts.  
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3.2 Results 
3.2.1 Clinical features of conjunctival and pterygial tissues 
In order to observe the histological structure of pterygium and conjunctiva tissue, 
hematoxylin-eosin (H&E) staining was carried out. It is notable that the structure of the 
two tissues differ as pterygium demonstrates more compact organization of fibroblasts 
showing intense eosin cytoplasmic staining (pink/red) (Figure 3.1A), while the conjunctiva 
tissue has a less dense arrangement of fibroblasts (Figure 3.1B). Conjunctival and 
pterygial tissue sections were also stained for alpha smooth muscle actin (SMA), which 
binds smooth muscle within the wall of blood vessels and serves as a marker of fibroblast 
to myofibroblast transdifferentiation. While the distinct epithelial and stromal layers are 
evident, it is also apparent that the two tissues are different. The first difference is the 
frequency of blood vessels, which are defined by the bright circular appearance of 
(SMA); in pterygium these are far more abundant (Figure 3.1C and D). The second 
difference is the increased level of SMA staining in the fibroblast cell population of 
pterygium, indicating transdifferentiation has occurred (Figure 3.1C and D).  
 
3.2.2 Concentration-dependent effects of serum on cell growth 
A concentration dependent effect of serum over a 48 hour culture period was observed 
with pterygial fibroblasts (Figure 3.2). Concentrations of 4%v/v FCS were required to 
produce a significant increase in growth compared with SF EMEM cultures. A peak  
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A B
C D
      
 
Figure 3.1. A comparison of cell organisation and tissue structure in pterygium (A & C) 
and normal conjunctival (B & D) tissue. (A & B) Haemotoxylin and eosin staining of 
sections derived from (A) apterygium and (B) conjuctiva. (C & D) Fluorescence 
micrographs showing aSMA expression (green) in (A) pterygium and (B) conjunctival 
tissue; sections were counterstained to visualise chromatin (blue) and the F-actin 
cytoskeleton (red). The field of view represents 800 X 571m (A&B) and 448 x 342 m 
(C&D). 
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Figure 3.2. Concentration-dependent effects of serum on cell growth of pterygial-derived 
fibroblasts detected using the MTS assay. The data represent means ± S.E.M. from 
experiments performed on pterygial derived fibroblasts from three different donors. Cells 
were exposed to experimental conditions for a 48 hour culture period. * indicates a 
significant difference between serum free maintained and serum treated group (p ≤ 0.05; 
ANOVA with Dunnett’s post hoc test). 
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response was obtained with 10% FCS addition, such that the cell population was 183 ± 
11.67% relative to non-stimulated Serum-free control.   
 
3.2.3 Intracellular calcium signalling 
To assess putative changes in calcium signalling in serum-maintained and serum-free 
conditions, we employed several agonists that are known to mobilise intracellular 
calcium. These ligands were histamine, ATP, ACh and EGF. Moreover, these ligands were 
selected because they have been associated with pterygium or have the potential to 
influence this condition. For example, active histamine and epidermal growth factor 
receptors have been determined in human pterygium (Maini, Collison et al. 2002). 
Extracellular ATP levels are also known to rise in stressed or pathological states (Eldred, 
Sanderson et al. 2003) and ACh is believe to influence cell function as a consequence of 
innervation, but can also transmit signals independent of innervation (Duncan and 
Collison 2003). 
 
In serum-maintained cells, histamine, ATP, ACh and EGF were shown to increase 
intracellular calcium levels through mobilisation of the ER calcium store in a 
concentration dependent manner. Significant elevation of intracellular calcium was 
observed with concentrations ≥ 10µM of histamine, ATP and ACh and 10ng/ml in the case 
of EGF. In contrast, cells maintained in serum-free medium and exposed to the four 
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ligands did not show any significant increase in intracellular calcium levels at any of the 
concentrations tested suggesting that serum deprivation can reduce the sensitivities of 
cell in response to these ligands. Responses obtained with histamine, ATP, ACh at 100µM 
and EGF at 10ng/ml differed significantly between the serum maintained and serum 
starved cells (Figure 3.3-3.6).  
 
Moreover, thapsigargin which is an intracellular Ca2+ pump inhibitor was applied to 
deplete the calcium store in pterygial fibroblasts in the presence and absence of serum 
and thus reveal the level of calcium stored within the ER. 1µM thapsigargin induced a 
significant increase in intracellular calcium level of cells maintained in serum and serum 
starved conditions (Figure 3.7). However, a significantly greater increase in calcium was 
observed in the serum maintained cells; the peak intracellular calcium level in serum free 
maintained cells group was 47% of that obtained in serum maintained cells (Figure 3.7). 
To assess the role of calcium influx, through store operated calcium entry, in the 
thapsigargin elevation of intracellular calcium experiments were performed in 
calcium-free extracellular medium (Figure 3.7). These experiments demonstrated an 
overall reduction in intracellular calcium levels in response to 1µM thapsigargin, but peak 
responses were not significantly different from cells treated in the presence of calcium in 
the extracellular medium. Therefore, ER store play a dominant role in mediating 
intracellular calcium mobilization. 
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In order to confirm that the ligand induced calcium responses involved the ER calcium 
store we pre-treated cells with thapsigargin for >1 hours to ensure the calcium store was 
drained. Control cells maintained in serum-free or serum, that exhibit a normal ER store, 
increased intracellular calcium in response to all ligands with a greater response observed 
in serum-maintained cells (Figure 3.8-3.11). In all cases, cells pre-treated with 
thapsigargin did not elicit an elevation in calcium in response to any of the four ligands 
tested. 
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Figure 3.3. Characterization of calcium mobilization in response to histamine in pterygial 
derived fibroblasts in the presence and absence of serum. Baseline calcium levels were 
established prior to injection of histamine after 15s as indicated; the ligand was retained 
in the bathing medium for the remainder of the experiment. The data represent means ± 
S.E.M. from experiments performed on pterygial derived fibroblasts from three different 
donors. * Indicates a significant difference from baseline;  Significant difference 
between serum maintained and serum starved groups (ANOVA with Turkey’s post hoc  
test, p ≤ 0.05). 
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Figure 3.4. Characterization of calcium mobilization in response to ATP in pterygial 
derived fibroblasts in the presence and absence of serum. Baseline calcium levels were 
established prior to injection of ATP after 15s as indicated; the ligand was retained in the 
bathing medium for the remainder of the experiment. The data represent means ± S.E.M. 
from experiments performed on pterygial derived fibroblasts from three different donors. 
* Indicates a significant difference from baseline;  Significant difference between serum 
maintained and serum starved groups (ANOVA with Turkey’s post hoc test, p ≤ 0.05). 
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Figure 3.5. Characterization of calcium mobilization in response to ACh in pterygial 
derived fibroblasts in the presence and absence of serum. Baseline calcium levels were 
established prior to injection of acetylcholine after 15s as indicated; the ligand was 
retained in the bathing medium for the remainder of the experiment. The data represent 
means ± S.E.M. from experiments performed on pterygial derived fibroblasts from three 
different donors. * Indicates a significant difference from baseline;  Significant 
difference between serum maintained and serum starved groups (ANOVA with Turkey’s 
post hoc test, p ≤ 0.05). 
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Figure 3.6. Characterization of calcium mobilization in response to EGF in pterygial 
derived fibroblasts in the presence and absence of serum. Baseline calcium levels were 
established prior to injection of EGF after 15s as indicated; the ligand was retained in the 
bathing medium for the remainder of the experiment. The data represent means ± S.E.M. 
from experiments performed on pterygial derived fibroblasts from three different donors. 
* Indicates a significant difference from baseline;  Significant difference between serum 
maintained and serum starved groups (ANOVA with Turkey’s post hoc test, p ≤ 0.05). 
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Figure 3.7. The effect of serum starvation on ER calcium store depletion in response to the CaATPase 
inhibitor thapsigargin in the presence and absence of extracellular calcium. The data represent 
means ± S.D. from experiments performed on pterygial derived fibroblasts from four different 
donors.* Indicates a significant difference from baseline;  Significant difference between serum 
maintained and serum starved groups (Student’s t test, p ≤ 0.05). 
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Figure 3.8. The effect of ER calcium store depletion by thapsigargin on histamine mediated calcium 
responses. Cells were maintained in control medium or exposed to 1µM thapsigargin for the final hour 
of culture prior to FURA-2 loading. Baseline calcium levels were established prior to injection of 
histamine after 15s as indicated; the ligand was retained in the bathing medium for the remainder of 
the experiment. The data represent means ± S.D. from experiments performed on pterygial derived 
fibroblasts from three different donors. * Indicates a significant difference from baseline;  significant 
difference between serum maintained and serum starved groups (ANOVA with Turkey’s post hoc test, 
p ≤ 0.05). 
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Figure 3.9. The effect of ER calcium store depletion by thapsigargin on ATP mediated calcium 
responses. Cells were maintained in control medium or exposed to 1µM thapsigargin for the final 
hour of culture prior to FURA-2 loading. Baseline calcium levels were established prior to injection 
of ATP after 15s as indicated; the ligand was retained in the bathing medium for the remainder of 
the experiment. The data represent means ± S.D. from experiments performed on pterygial 
derived fibroblasts from three different donors. * Indicates a significant difference from baseline; 
 significant difference between serum maintained and serum starved groups (ANOVA with 
Turkey’s post hoc test, p ≤ 0.05). 
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Figure 3.10. The effect of ER calcium store depletion by thapsigargin on ACh mediated calcium 
responses. Cells were maintained in control medium or exposed to 1µM thapsigargin for the final 
hour of culture prior to FURA-2 loading. Baseline calcium levels were established prior to injection 
of ACh after 15s as indicated; the ligand was retained in the bathing medium for the remainder of 
the experiment. The data represent means ± S.D. from experiments performed on pterygial 
derived fibroblasts from three different donors. * Indicates a significant difference from baseline; 
 significant difference between serum maintained and serum starved groups (ANOVA with 
Turkey’s post hoc test, p ≤ 0.05). 
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Figure 3.11. The effect of ER calcium store depletion by thapsigargin on EGF mediated calcium 
responses. Cells were maintained in control medium or exposed to 1µM thapsigargin for the final 
hour of culture prior to FURA-2 loading. Baseline calcium levels were established prior to injection 
of EGF after 15s as indicated; the ligand was retained in the bathing medium for the remainder of 
the experiment. The data represent means ± S.D. from experiments performed on pterygial 
derived fibroblasts from three different donors. * Indicates a significant difference from baseline; 
 significant difference between serum maintained and serum starved groups (ANOVA with 
Turkey’s post hoc test, p ≤ 0.05). 
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3.2.4 The effects of calcium signalling disruption on cell growth and 
migration 
To determine the importance of calcium signalling on pterygial cell function, we 
employed several assays to evaluate growth and migration. A patch assay was initially 
used to assess coverage of cells on a tissue culture dish. 1μM thapsigargin was used to 
disrupt calcium signalling. Thapsigargin treated cells covered a significantly smaller area, 
such that area covered was 65.3 ± 9.34% that of the control group (Figure 3.12C). Cell 
population numbers also differed significantly; in this case thapsigargin treated cells were 
86.3 ± 2.73% compared with controls (Figure 3.12D). These data suggested an effect on 
both migration and cell growth. We then expanded on these findings and employed an 
MTS assay to further evaluate effects on cell populations and a scratch assay to study 
effects on migration. The MTS assay showed a similar outcome to the patch assay, such 
that populations in the thapsigargin treated group were 81.7 ± 5.3% of the 
non-stimulated group (Figure 3.13). The scratch wound assay clearly demonstrated the 
ability of thapsigargin to inhibit coverage of the wounded area (Figure 3.14). Within 24 
hours, control cells have rapidly covered the cell-free area, whereas progress is 
significantly retarded in the thapsigargin treated group.  
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Figure 3.12. The effect of thapsigargin on pterygial-derived fibroblast growth detected 
using the patch assay. Pterygial fibroblasts were cultured for 48 hours in EMEM 
supplemented with 10% FCS only (A) or treated with 1μM thapsigargin (B); the coverage 
(C) and number (D) of cells were assessed. The data represent means ± S.D. from 
experiments performed on pterygial derived fibroblasts from three different donors. * 
indicates a significant difference between non-stimulated control and treated group (p ≤ 
0.05; Student’s t test). 
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Figure 3.13. Effects of thapsigargin on cell growth of pterygial-derived fibroblasts 
detected using the MTS assay. Pterygial fibroblasts were cultured for 24 hours in EMEM 
supplemented with 10% FCS ± 1μM thapsigargin. The data represent means ± S.D. from 
experiments performed on pterygial derived fibroblasts from three different donors. * 
indicates a significant difference between non-stimulated control and treated group (p ≤ 
0.05; Student’s t test). 
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Figure 3.14. Effects of thapsigargin on cell migration of pterygial-derived fibroblasts 
detected using the scratch assay. Pterygial fibroblasts were cultured for 24 hours in 
EMEM supplemented with 10% FCS ± 1μM thapsigargin (A). The cell movement is 
significantly retarded in the thapsigargin treated group (B). The data represent means ± 
S.D. from experiments performed on pterygial derived fibroblasts from three different 
donors. * indicates a significant difference between non-stimulated control and treated 
group (p ≤ 0.05; Student’s t test). 
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3.2.5 Genes up-regulated and down-regulated by 10% serum in pterygial 
derived fibroblasts 
A total of 104 genes were up-regulated by more than 2 fold in pterygial fibroblast in 
response to 10% serum. Many of these up-regulated genes have biological functions of 
relevance to pterygium, such as cell cycle division, growth, proliferation, differentiation 
and contraction. A total of 53 genes were down-regulated by more than 2 fold in 
pterygial fibroblast following the treatment with 10% serum. Many of these 
down-regulated genes have biological functions associated with regulation of cholesterol 
biosynthesis, anti-angiogenesis, and negative regulation of cell growth, differentiation 
and transcriptional activities. The 50 genes showing the greatest level of increase and 
decrease in response to serum are shown in Appendix I.  
 
3.2.6 Gene expression profile of histaminergic, purinergic, cholinergic and 
EGF receptors in pterygial fibroblasts 
Four histamine receptor HRH1, 2, 3 and 4 were detected in pterygial fibroblast giving a 
low baseline signal value (Figure 3.15). Gene expression of these receptors was 
unchanged following treatment with 10% serum (Figure 3.15). Of the 18 cholinergic 
receptors, both muscarinic and nicotinic receptor subtypes were detected in pterygial 
fibroblasts, the majority of these genes were associated with a relatively low signal. 
Nicotinic α5 and β1 had a relatively higher baseline signal (Figure 3.15). The gene 
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expression of all cholinergic receptors remained unchanged following addition of 10% 
serum (Figure 3.15). Epidermal growth factor (EGF) receptor was detected and again 
expression was unaffected by 10% serum exposure. Of the 20 purinergic receptors (P2X 
and P2Y subtypes) all were detected in pterygial fibroblasts, these receptors show varying 
baseline signal values with P2RX4 and P2RY5 having relatively higher signal values (Figure 
3.15). However, only P2RY5 was down-regulated 1.3 fold and other purinergic receptors 
remained unchanged following treatment with 10% serum (Figure 3.15). All three IP3 
receptors are present in pterygial fibroblasts. Type1 and 3 were detected with a high 
baseline signal relative to IP3R1 (Figure 3.16). IP3R1 was down-regulated 1.3 fold, 
following treatment with 10% serum, while expression of the other two IP3 receptor gene 
expressions were unchanged (Figure 3.16). Three SERCA Ca2+-ATPases were detected in 
pterygial fibroblasts. ATP2A2 had the highest baseline signal value; serum treatment had 
no effect on expression. 19 phospholipase C family members were detected with varying 
baseline signal values; PLCD1, D3, G1, L2 and XD1 had relatively high signal levels. PLCL2 
was down-regulated 1.3 fold and PLCXD3 was up-regulated 1.3 fold while gene 
expressions of all other members remained unchanged with exposure to serum. The 
guanine nucleotide binding protein (GNAQ) is expressed in pterygial cells and its gene 
expression pattern was unchanged by 10% serum.  
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Figure 3.15. A gene expression profile of histaminergic, purinergic, cholinergic, EGF 
receptors detected in pterygial fibroblasts. The data are presented in a colorimetric form 
to indicate the relative level of signal detected for each gene in non-stimulated 
serum-free controls using microarrays. Fold changes were detected in gene expression 
following 24 hours culture in 10% serum relative to serum-free controls. Data are derived 
from the mean value of 4 separate experiments. 
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Figure 3.16. A gene expression profile of calcium signalling components detected in 
pterygial fibroblasts. The data are presented in a colorimetric form to indicate the 
relative level of signal detected for each gene in non-stimulated serum-free controls 
using microarrays. Fold changes were detected in gene expression following 24 hours 
culture in 10% serum relative to serum-free controls. Data are derived from the mean 
value of 4 separate experiments. 
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3.2.7 Angiogenesis factors expression 
Proteome Profiler™ Array data revealed that pterygial-derived fibroblasts release 
angiogenic factors into the bathing medium (Figure 3.17). 24 proteins were detectable 
using image analysis software (Image J). Of these, 19 have been reported to be 
pro-angiogenic factors and five anti-angiogenic factors (Figure 3.18). Serum exposure 
resulted in a significant increase IL-8 protein level to 181.48% ± 39.24%, MMP9 to 
122.77% ± 7.48%, VEGF to 186.62% ± 53.77% and MCP-1 115.67% ± 7.29%, but 
significantly reduced the levels of Insulin-like growth factor-binding protein 3 (IGFBP-3) to 
75.94 ± 10.56%, FGF-4 to 60.58 ± 17.05%, EG-VEGF to 56.14 ± 11.25%, IGFBP-1 to 33.33 ± 
33.85%, artemin to 48.28 ± 13.04%, FGF-1 to 39.18 ± 33.7%, angiogenin-1 to 38.06 ± 
21.9%, platelet derived growth factor-AA (PDGF-AA) to 36.67 ± 5.04%, IL-1β to 22.29 ± 
19.4% and fibroblast growth factor 2 (FGF-2) to 15.16 ± 22.6% when compared with 
untreated control SF EMEM control. Serum maintenance also affected the 
anti-angiogenic proteins, such that it significantly decrease angiostatin protein expression 
to 17.8 ± 8.2%, SerpinE1 to 66.75 ± 20.4%, metallopeptidase inhibitor 1 (TIMP-1) to 65.11 
± 20.2% and thrombospondin-1 to 42.62 ± 12.5% of SF EMEM control.  
 
    
   
 
71 
 
A
B
C
D
E
F
11 12 13 14 15 16 17 18 19 20 21 22 23 241 2 3 4 5 6 7 8 9 10
Serum-free
10%  FCS EMEM
A
B
C
D
E
F
11 12 13 14 15 16 17 18 19 20 21 22 23 241 2 3 4 5 6 7 8 9 10
 
 
 
Figure 3.17. The human angiogenesis array detects multiple analytes in serum free and 
10% serum pterygial-derived fibroblasts culture supernatants. Array images were 
exposure in the X-RAY film and the detectable protein spots were labelled on the film. 
The coordinate reference for analyte identification is listed in the Methods section, Table 
2.2. 
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Figure 3.18. Proteome profile of angiogenic factors released from pterygial-derived 
fibroblasts maintained in the presence or absence of serum for a 24 hour period. The 
data represent means ± S.D. compiled from three separate experiments. * Indicates a 
significant difference between serum maintained and serum starved groups (Student’s 
ttest, p ≤ 0.05). 
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3.3 Discussion 
Pterygium exhibits a high degree of vasculature relative to normal conjunctiva. The 
pro-angiogenic VEGF has been identified in pterygial specimens and its presence links in 
well with the abundance of blood vessels (Liang, Jiang et al. 2012). Therapeutic 
approaches using anti-VEGF have been used and some benefit has been reported (Leippi, 
Grehn et al. 2009). It was therefore of interest to determine the importance of this rich 
vasculature and determine the impact of restricting nutrient supplies to pterygial cells. A 
simple approach was used, which involved serum maintenance or serum starvation; the 
intention of this strategy was to mimic an environment that has a rich or diminished 
blood supply and one that is poor. As predicted a progressive decrease in cell growth was 
observed as serum levels declined. Pterygial cells are therefore reliant on a supply of 
growth and survival factors. Having established that serum starvation reduces cell growth, 
analysis of calcium signalling was performed.  
 
Pterygial tissue is characterized by extensive cellular proliferation, transdifferentiation 
and angiogenesis which is linked to Ca2+ signalling activities (Coroneo, Di Girolamo et al. 
1999). The endoplasmic reticulum (ER) is the main intracellular Ca2+ store/release 
organelle. The cells can either elevate cytosolic Ca2+ by releasing Ca2+ from the 
intracellular store or uptake Ca2+ into the cell from extracellular solution. Store-operated 
Calcium entry (SOCE) is the dominant Ca2+ entry pathway (Parekh and Penner 1997). In 
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my study, Histamine, ATP, Acetylcholine and epidermal growth factors were evaluated 
for their effect on intracellular calcium levels of pterygial fibroblasts in the presence and 
absence of serum.  All ligands demonstrated a reduced ability to raise intracellular 
calcium concentration following serum starvation. It demonstrates that receptors are 
available on the surface of pterygial cells. The active histamine and epidermal growth 
factor receptors have been determined in human pterygium (Maini, Collison et al. 2002). 
Calcium signalling is impaired and may be the result of differences in receptor expression 
or modification of signalling molecules common to these ligand/receptor systems. In 
gene microarray analysis, four histamine receptors H1, 2, 3 and 4 were detected in 
pterygial fibroblast but their receptors gene expressions were unchanged following 
treatment with 10% serum. HRH1 is the dominant receptor and is known to elevate 
intracellular Ca2+ level (Francis, Glaser et al. 2008). Mast cells that can produce histamine 
and in pterygium these cells are nearly twice as abundant as observed in normal 
conjunctiva (Nakagami, Murakami et al. 1999). Therefore, a rich blood supply is likely to 
maintain the stimulation of pterygial cells by the enhanced levels of histamine available. 
Moreover, due to the inflammatory nature of pterygium the histamine stored in mast 
cells is likely to be released. Muscarinic and nicotinic acetylcholine receptors were 
detected in pterygial fibroblasts. Cholinergic nicotinic receptor α5 and β1 had the 
relatively high baseline signal. They belong to nicotinic acetylcholine receptor superfamily 
and are triggered by the binding of the neurotransmitter acetylcholine (ACh) to form 
ligand-gated ion channels that mediate signal transmission across plasma membrane 
    
   
 
75 
 
(Brejc, van Dijk et al. 2001). It is reported that nACh can modulate endothelial cell 
survival, proliferation, and migration to result in pathological angiogenesis (Heeschen, 
Jang et al. 2001; Cooke and Ghebremariam 2008). The receptors may be activated by 
acetylcholine or nicotine to induce endothelial-cell growth and tube formation and 
accelerate fibrovascular growth in pathophysiological disorder (Heeschen, Jang et al. 
2001; Zhu, Heeschen et al. 2003). Muscarinic receptors M1, M3 and M5 were suggested 
to play a role in intracellular Ca2+ by coupling to G proteins to activate phospholipase C 
(Caulfield 1993). The gene expression of all acetylcholine receptors remained unchanged 
following addition of 10% serum. Epidermal growth factor (EGF) receptor was expressed 
but showed no change in expression in 10% serum relative to serum-free medium. ATP 
purinergic receptors (P2X and P2Y) were detected in pterygial fibroblasts. The purinergic 
receptor P2Y, G-protein coupled 4 and 5 were abundant under non-stimulated conditions. 
However, P2RY5 was down-regulated following treatment with 10% serum. P2Y G 
protein-coupled receptor functions as a receptor for extracellular ATP and ADP and 
mobilizes intracellular calcium ions via activation of phospholipase C (Abbracchio, 
Burnstock et al. 2006). Recent studies have suggested that both ATP-gated P2X (ion 
channel) and P2Y (G protein-coupled) signalling may contribute to platelet aggregation, 
cell proliferation, differentiation and migration in human vascular diseases (Gachet 2006; 
Erlinge and Burnstock 2008). However, these ligands can stimulate a number of pathways 
in cells. Scrutiny of calcium signalling components within the gene array data provided 
assessment of changes at the message level. Many studies have investigated inositol 
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trisphosphate in calcium signalling, inositol 1, 4, 5-trisphosphate (IP3) is a secondary 
messenger molecule used in signal transduction in cells. It is produced by phospholipase 
C pathway (PLC) which catalyses the hydrolysis of phosphatidylinositol 4, 5-bisphosphate 
(PIP2) (Berridge 1993; Clapham 1995; Bootman, Collins et al. 2001). With regard to IP3 
receptors present on the microarray, type1 and 3 were detected with high baseline 
signals and IP3R1 was down-regulated by 10% serum in pterygial fibroblasts. Of the 19 
phospholipase C family members, PLCD1, D3, G1, L2 and XD1 had relatively high signal 
levels. PLCL2 was down-regulated and PLCXD3 was up-regulated with abundance of 
serum. A study suggested that PLC like-2 protein is involved in IP3 regulation around 
endoplasmic reticulum (ER) (Otsuki, Fukami et al. 1999). PLCX-domain containing protein 
3 was identified in cytoplasm and suggested different functions in animal models in a 
recent study (Gellatly, Kalujnaia et al. 2010). Above all, explicitly linking calcium 
mobilization to a specific function is not straightforward. To demonstrate a functional 
consequence of calcium signalling we have determined the effects of calcium signalling 
ablation, using intracellular Ca2+ pump inhibitor thapsigargin to investigate the effects on 
pterygial fibroblast proliferation and migration. However, all ligands show a similar 
pattern of response which suggests that a common factor is changing. To address this 
issue we concentrated our efforts on the calcium store itself. The Ca2+ATPase inhibitor 
thapsigargin can be used to establish store content. It depletes the ER store slowly and 
evokes the cytosolic free Ca2+ without elevation in inositol polyphosphates (Parekh and 
Penner 1997). Application of thapsigargin to cells maintained in serum free medium 
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demonstrated that the calcium level within the endoplasmic reticulum store was 
depleted relative to serum maintained cells. Therefore, these data illustrate that 
intracellular calcium stores are sensitive to serum deprivation: this could have a marked 
effect on cell behaviour. The ER calcium store is regulated by a number of components. 
The receptor channels inositol-1, 4, 5-phosphtate- (IP3R) and ryanodine-receptors (RYR) 
release Ca2+ from intracellular stores (Bergner and Huber 2008). Therefore reduction in 
these channels would impair release from the store. In addition, 
sarcoplasmic/endoplasmic reticulum-CaATPASE (SERCA), is an ER trans-membrane 
protein that pumps calcium back into the ER; without this pump calcium recruitment in 
the ER cannot occur.  The gene expressions of SERCA Ca2+-ATPases were detected in 
pterygial fibroblasts and ATP2A2 had correspondingly high baseline signal values. ATP2A2 
encoded SERCA Ca2+-ATPases are intracellular pumps located in the sarcoplasmic or 
endoplasmic reticula of muscle cells, it is involved in regulation of the contraction and 
relaxation cycle (Sakuntabhai, Ruiz-Perez et al. 1999). Further regulation can occur within 
the ER: Calreticulin (CRT) and calsequestrin (CASQ) are two major Ca2+ -binding proteins 
inside the ER membranes that act as Ca2+ buffers (Milner, Famulski et al. 1992; Mery, 
Mesaeli et al. 1996; Bergner and Huber 2008). Both calreticulin and calsequestrin play a 
critical role in Ca2+ homeostasis in the lumen of the ER (Michalak, Corbett et al. 1999; 
Beard, Laver et al. 2004). Calsequestrin is a regulator of RyR activity and many studies 
show that it regulates protein synthesis (Helenius, Trombetta et al. 1997; Saito, Ihara et 
al. 1999) while calreticulin is a versatile lectin-like chaperone and also has been 
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implicated in a variety of cellular functions (Michalak, Corbett et al. 1999). The major 
function of these Ca2+-binding chaperones is to increase the Ca2+ storage capacity of the 
ER lumen.  Therefore, expression of such proteins is vital for active calcium signalling. 
Scrutiny of these expression patterns in serum-maintained and serum-deprived cells will 
be a worthwhile topic of study in the future.  
 
Having demonstrated that the ER store can be modulated by serum deprivation it was 
important to determine a functional role for calcium signalling in pterygium. The agonists 
used to assess changes in calcium signalling can stimulate a number of pathways; 
therefore explicitly linking calcium mobilization to a specific function by a ligand isn’t 
straightforward. Further investigation of the signalling pathways activated by these 
ligands and their functional roles in pterygium will be a valuable topic of investigation in 
the future. However, to demonstrate a functional consequence of calcium signalling it 
was necessary to utilise thapsigargin to deplete the store and disrupt signalling. Using this 
approach we have shown that disruption of the ER store and thus calcium signalling could 
affect cell growth and migration of pterygial-derived fibroblast. This suggests that 
regulation of the ER store is an important consideration in the management of pterygium. 
These data tie in well with studies in other cells and tissues that have demonstrated that 
the ER store is required for cell division (Wang, Wormstone et al. 2005) and 
migration.(Duncan, Wormstone et al. 1997; Nicola, Timoshenko et al. 2005) Persistent 
depletion of the store can result in reduced protein synthesis, ER stress and 
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apoptosis.(Shi, Wang et al. ; Nicola, Timoshenko et al. 2005; Wang, Wormstone et al. 
2005; Zhang, Duncan et al. 2007) It is feasible that serum starvation over prolonged 
periods of time could lead to an increasingly diminished store. This in turn could affect 
basic functions associated with the progression of pterygium. In the first instance a 
reduction in migration and proliferation would be predicted followed by ER stress lead 
processes such as reduced protein synthesis and potentially cell death by apoptosis.(Shi, 
Wang et al. ; Nicola, Timoshenko et al. 2005; Wang, Wormstone et al. 2005; Zhang, 
Duncan et al. 2007) Applying this principle to the clinic, strategies that reduce the blood 
supply to the pterygium, such as anti-VEGF (Leippi, Grehn et al. 2009), could facilitate a 
reduction of calcium in the ER store; when this reaches a threshold, cell functions will be 
impaired leading to reduced growth and potentially cell death. Future work into calcium 
signalling and the store per se should examine the effects of long-term depletion of the 
ER store and ER stress related events in relation to cell growth, migration and survival of 
pterygial fibroblasts when considering putative therapies. 
 
 
It is evident that a rich blood supply is required to facilitate growth and migration of 
pterygial cells and that modification to this nutrient supply affects signalling potential, 
which provides a rational reduced cell growth. It is therefore of interest to assess the 
effect of serum on the promotion of angiogenenic factor release by fibroblasts and their 
role in the maintenance of the high level of vasculature in pterygia.  
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Using a Proteome Profiler™ Array, it was found that serum was capable of promoting 
release of pro-angiogenic factors and suppressing the anti-angiogenic factors. This 
suggests that if a rich blood supply exists it is likely to fuel continued production of new 
blood vessels that will further enrich the pterygial cell environment and progress the 
disease at a more rapid rate.  
 
Interleukin 8 is a major mediator of the inflammatory response and potent angiogenic 
factor in many human diseases (Huang, Mills et al. 2002; De Paepe, Creus et al. 2012; 
Welling, Fu et al. 2012). IL8 was up-regulated in response to 10% serum and is reported 
to be involved in ultraviolet radiation initiated blood vessel formation, inflammation and 
cellular proliferation in pterygium (Di Girolamo, Kumar et al. 2002). As UV is an initiating 
factor in pterygia then IL8 is an interesting topic for future investigations. MMP9 was also 
found to increase in the medium of serum maintained cells. A recent study suggested 
that pterygium cells may produce the MMPs to stimulate stromal fibroblasts growth by 
dissolving Bowman's layer (Reid and Dushku 2010). MMP-9 was found highly expressed 
in advanced stage pterygial tissues and fibroblasts which propose to play a role in 
progression of pterygium (Naib-Majani, Eltohami et al. 2004; Yang, Lin et al. 2009). 
Monocyte chemoattractant protein-1 (MCP-1) was elevated in the presence of serum and 
has previously been identified as a TGFβ target gene in endothelial cells (ECs) (Ma, Wang 
et al. 2007). It reported that MCP-1 mediates TGFβ–stimulated angiogenesis by 
increasing cell migration and promoting the formation of blood vessels in vivo, it plays a 
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direct role in wound healing, angiogenesis and tumour progression (Salcedo, Ponce et al. 
2000; Low, Drugea et al. 2001; Ma, Wang et al. 2007). Most interestingly, vascular 
endothelial growth factor (VEGF) was up-regulated significantly by 10% serum. As a 
vascular permeability factor, it is potent mitogen acting on the endothelium. In the 
presence of this growth factor, plated endothelial cells will proliferate, migrate and 
recruit new capillaries. It plays important roles in angiogenic diseases (Ferrara and 
DavisSmyth 1997). The current data confirms that in abundant serum environment 
pterygial fibroblasts are more like to synthesise and release VEGF to promote 
angiogenesis and the cells still release VEGF to maintain this rich environment.  
 
With regard to anti-angiogenic factor, 10% serum significantly reduced the protein 
production of anti-angiogenic factors angiostatin, SerpinE1, TIMP-1 and 
Thrombospondin-1. Angiostatin was reported an angiogenesis inhibitor that suppress 
neovascularisation and growth of metastases in mouse tumour (Oreilly, Holmgren et al. 
1994). As protease inhibitors, serpins locate in blood plasma and are involved in 
angiogenic processes like regulating blood clotting, the complement pathway and 
extracellular matrix remodelling (Potempa, Korzus et al. 1994).  SerpinE1 inhibits the 
activity of matrix metalloproteinases to regulate the progression to fibrosis (Irigoyen, 
Munoz-Canoves et al. 1999). Thrombospondin-1 is a potent inhibitor of angiogenesis; it 
interacted with ECs surface receptor CD36 to inhibit the proliferation and migration of 
endothelial cells (Reiher, Volpert et al. 2002). It was reported p53 can positively activate 
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endogenous TSP-1 gene expression to inhibit angiogenesis in fibroblasts (Dameron, 
Volpert et al. 1994). Tissue inhibitors of metalloproteinases function as inhibitors of 
angiogenic factors, matrix metalloproteinases and induction of apoptosis (Brew, 
Dinakarpandian et al. 2000), it was demonstrated that TIMP-1 can potentially inhibit 
pterygium invasion (Tsai, Chiang et al. 2010).  
 
It seems evident that serum can promote the release of pro-angiogenic factors and 
suppress the release of anti-angiogenic factors. It should however be noted that 
angiogenic factors are still released from cells maintained in serum-free conditions. While 
the net potential of these cells to promote angiogenesis is less than their serum cultured 
counterparts they still feasible could promote angiogenesis to some degree. The reason 
of this phenomenon may result from that pterygial fibroblast in serum free medium 
releasing pro-angiogenic signals in order to promote new blood vessel formation, which 
could sustain their survival through nutrient enrichment. It has been reported that serum 
deprivation could induce low oxygen pressure and nutrition depletion (Baek, Jang et al. 
2000). Hypoxia can activate hypoxia-inducible factor (HIF) to increase VEGF to benefit 
angiogenesis (Risau 1997; Pousa and Gisbert 2006). The current data support the 
previous studies that hypoxia mediates angiogenesis by up-regulation of VEGF and 
various angiogenic factors like FGF-2, IGFBP-1 and angiogenin (Tazuke, Mazure et al. 1998; 
Hartmann, Kunz et al. 1999; Kroon, Koolwijk et al. 2001). Therefore, both serum starved 
and maintained conditions could induce the pro-angiogenic factor release from pterygial 
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derived fibroblast from different mechanisms. However, except IGFBPs all up-regulated 
angiogenic factors by SF EMEM show very weak protein signal level compared with 
serum maintained condition.  
 
A rich blood supply can fuel cell growth and migration retain efficient calcium signalling 
and has the potential to further enrich the vasculature within pterygial tissue. The data 
therefore support the notion that restriction of the blood supply in pterygium will be of 
therapeutic benefit to patients. 
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CHAPTER 4 
TGFβ signalling in pterygial fibroblasts 
 
4.1 Introduction 
Transforming growth factor beta (TGFβ) is a typical mediator and master switch of 
fibrosis (Sime and O'Reilly 2001). It involves in the regulation of cell behaviour in ocular 
tissues. A study suggested TGFβ can induce eye inflammatory responses as well as tissue 
fibrosis (Connor, Roberts et al. 1989). It is expressed more in epithelial and stromal layers 
of pterygium compared to similar regions in normal conjunctiva (Bianchi, Scarinci et al. 
2012). TGFβ is believed to play a critical role in inducing transdifferentiation and 
regulation of the extracellular matrix (Desmouliere, Geinoz et al. 1993; Miettinen, Ebner 
et al. 1994). Both TGFβ1 and TGFβ2 are reported to stimulate myofibroblast formation 
and expression of alpha SMA in different human ocular cells (Lee, Kwon et al. 2001; 
Wormstone, Tamiya et al. 2002). In the anterior segment of the human eye, TGFβ2 was 
found to be predominant in superficial limbal epithelial cells, conjunctival stroma and 
human aqueous humour (Jampel, Roche et al. 1990; Pasquale, Dormanpease et al. 1993). 
TGFβ2 could increase the expression of cell adhesion receptors termed integrins on the 
surface of cells to control cell proliferation and differentiation (Ignotz and Massague 
1987). Furthermore, over-expression of TGFβ may play an important role in the 
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pathogenesis of pterygium by increasing angiogenesis and lead to the formation of new 
blood vessels from the pre-existing vasculature (Kria, Ohira et al. 1996; Sun and Ke 2007; 
Bianchi, Scarinci et al. 2012). However, the pathogenesis of fibrotic activity in pterygium 
still needs further investigation. The present study aimed to understand the effects of the 
inflammatory cytokine TGFβ signalling events on pterygial-derived fibroblasts and 
contribution with respect to Smad2/3 signalling, transdifferentiation and angiogenesis 
which could contribute to the process of this disease. 
 
4.2 Results 
4.2.1 TGFβ/Smad signalling in pterygial fibroblasts 
5000 cells in 100l were seeded on a square sterile coverslip housed in a tissue culture 
dish. Cells were allowed to establish and then placed in serum-free medium for 24 hours 
prior to addition of TGFβ. Over 20 cell nuclei on each image were quantified. 
Immunocytochemistry revealed that Smad2/Smad3 was translocated to the nucleus in 
response to TGFβ1 and 2 in pterygial fibroblasts (Figure 4.1-4.2). Non-stimulated (control) 
cells did not demonstrate significant levels of nuclear Smad2/3 over the experimental 
duration. Stimulation with 0.001ng/ml TGFβ1 or 2 did not induce a significant 
mobilization of Smad2/3 to the nucleus relative to control cells at any time point studied 
(Figure 4.3-4.4). Application of 0.01ng/ml TGFβ2 again did not show a significant 
accumulation of Smad2/3 against control (Figure 4.4), but stimulation was observed with 
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application of 0.01ng/ml TGFβ1 at the 120min time-point (Figure 4.3). Addition of TGFβ1 
and TGFβ2 at 0.1ng/ml leads to a marked translocation of Smad2/3 to the nucleus (Figure 
4.3-4.4). TGFβ1 invoked a significant accumulation of Smad2/3 that was first observed 
following a 30 min exposure period, whereas this change was first observed with TGFβ2 
at the 1 hour time point. Stimulation with 1ng/ml TGFβ1 or TGFβ2 gave the greatest 
response of all concentrations tested. Significant changes in nuclear Smad2/3 were seen 
following 30 minutes and remained elevated for the experimental duration. With both 
isoforms peak Smad2/3 accumulation was observed at the 120 min time point. 
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0.001ng/ml 0.01ng/ml 0.1ng/ml 1ng/ml 
 
Figure 4.1. Fluorescent micrographs showing Smad 2/3 distribution in pterygial-derived 
fibroblasts following TGFβ1 stimulation. Smad 2/3 is depicted as green. The field of view 
in each case represents 448 x 342 m.     
    
   
 
88 
 
control
 
0.001ng/ml 0.01ng/ml 0.1ng/ml 1ng/ml 
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Figure 4.2. Fluorescent micrographs showing Smad 2/3 distribution in pterygial-derived 
fibroblasts following TGFβ2 stimulation. Smad 2/3 is depicted as green. The field of view 
in each case represents 448 x 342 m. 
 
 
    
   
 
89 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100 120 140 160 180 200 220 240
%
 M
ax
 S
ig
n
al
Time(minutes)
TGFbeta1 dose response vs time
0.001ng/ml
0.01ng/ml
0.1ng/ml
1ng/ml
*
*
*
*
*
*
*
*
*
 
 
Figure 4.3. TGFβ1 induced Smad 2/3 translocation into the nuclei of pterygial fibroblasts 
as a function of dose and time. The data represent means ± S.E.M. compiled from three 
separate experiments. * indicates a significant difference between non-stimulated 
control and treated group (p ≤ 0.05; ANOVA with Dunnett’s post hoc test). 
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Figure 4.4. TGFβ2 induced Smad 2/3 translocation into the nuclei of pterygial fibroblasts 
as a function of dose and time. The data represent means ± S.E.M compiled from three 
separate experiments. * indicates a significant difference between non-stimulated 
control and treated group (p ≤ 0.05; ANOVA with Dunnett’s post hoc test). 
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4.2.2 Transdifferentiation of pterygial fibroblasts 
In order to determine the effect of serum, TGFβ1 and TGFβ2 on pterygial fibroblast 
transdifferentiation to a myofibroblast, expression of αSMA was used as a marker. This 
evaluation was carried out on cultured pterygial fibroblasts derived from three different 
donors. Real-time PCR was performed to assess αSMA gene expression. 10% serum was 
found to promote αSMA expression to levels of 255.33% ± 262.1% compared to 
non-stimulated controls (Figure 4.5). Treatment of pterygial fibroblasts with 1ng/ml 
TGFβ1 caused a 488.06 ± 390.1% increase in αSMA expression when compared to control. 
TGFβ2 (1ng/mL) stimulation resulted in a significant increase in gene expression to 
491.33 ± 237.3% in comparison with control (Figure 4.5). 
  
Similarly, Western blot analysis reveals that αSMA was expressed in pterygial fibroblasts. 
There were weak but detectable bands in serum free controls, but αSMA protein was 
up-regulated following 24 hours stimulation with serum, such that expression levels rose 
to 154.85% ± 36.93% compared with non-stimulated control cells. In addition, the αSMA 
protein was also up-regulated with TGFβ2. in this case protein levels increased to 365.37 
± 326.4% compared to the control group (Figure 4.6).   
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Figure 4.5. αSMA gene expression in pterygial fibroblasts detected using QRT-PCR. The 
data represent means ± S.D. compiled from three separate experiments.  TGFβ 
concentration applied was 1ng/ml. * Indicates a significant difference between treated 
and control groups (Student’s ttest, p ≤ 0.05).  
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Figure 4.6. Protein level of αSMA was detected in pterygial fibroblasts using the Western  
blot method. Pterygial-derived fibroblasts maintained in the presence or absence of 
TGFβ2 for a 24 hour period. The data represent means ± S.D. compiled from four 
separate experiments.   
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4.2.3 Angiogenic factors expression 
Proteome Profiler™ Array data revealed that pterygial-derived fibroblasts release 
angiogenic factors into the bathing medium. 31 proteins were detectable using image 
analysis software (Image J) from three separate experiments (Figure 4.7). 24 of these 
factors are reported to be pro-angiogenic and 7 are anti-angiogenic factors. 
Measurement of the cell culture supernatant revealed the protein profile associated with 
each treatment (Figure 4.7). The data reveals that the release of angiogenic factors, 
namely fibroblast growth factor 1, 2, 4, 7, amphiregulin, IL-1β, persephin, LAP(TGFβ), 
placental growth factor (PlGF), PDGF-AA, Artemin, Prolactin, Angiopoietin-1 and 
Angiogenin were up-regulated significantly in response to 1ng/ml TGFβ2 in pterygial 
fibroblast. Importantly, TGFβ2 exposure resulted in a significant increase in production of 
IL-8 to 542.3 ± 107.97%, VEGF to 183.93 ± 23.64%, EG-VEGF to 166.83 ± 17.65%, 
endothelin-1 to 167.3 ± 20.33%, , MMP9 to 160.08% ± 8% and angiogenin 166.83 ± 
17.65% when compared with untreated control medium (Figure 4.8). TGFβ2 stimulation 
also affected the release of anti-angiogenic proteins; it significantly activates production 
of angiostatin, Thrombospondin-2 and Platelet Factor 4 (Figure 4.8). 
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Figure 4.7. The human angiogenesis array detects multiple analytes in serum free and 
TGFβ2 treated pterygial-derived fibroblasts culture supernatants. Array images were 
exposure in the X-RAY film and the detectable protein spots were labelled on the film. 
The coordinate reference for analyte identification is listed in the Methods section, Table 
2.2. 
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Figure 4.8. Proteome profile of angiogenic factors released from pterygial-derived 
fibroblasts maintained in the presence or absence of 1ng/ml TGFβ2 for a 24 hour period. 
The data represent means ± S.D. compiled from three separate experiments. * Indicates 
a significant difference between TGFβ2 treated and serum free control groups (Student’s 
ttest, p ≤ 0.05).   
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4.2.4 Gene array 
4.2.4.1 Gene up-regulated and down-regulated by TGFβ2 in pterygial 
derived fibroblasts 
Following treatment with TGFβ2, the differential changes in gene expression detected by 
Illumina microarrays. A total of 198 genes were up-regulated by more than 2 fold in 
pterygial fibroblast by TGFβ2 in four biological replicates. Many of these up-regulated 
genes had biological functions relevant roles in cell growth, proliferation, contraction, 
transdifferentiation, tissue remodelling, signal transduction and angiogenesis. A total of 
197 genes were down-regulated by more than 2 fold in pterygial fibroblast treated with 
TGFβ2. Many of these down-regulated genes have biological functions including roles in 
signalling, anti-angiogenesis and as suppressors of cell growth and differentiation. The 
highest 50 up-regulated and down regulated genes by TGFβ2 were listed with gene 
information in the Appendix I.  
 
4.2.4.2 Gene expression profile of growth factor and their receptors in 
pterygial fibroblasts 
TGFβR2 and TGFβR3 were detected in pterygial fibroblast (Figure 4.9) giving a higher 
baseline signal value compared to TGFβR1 while its baseline signal was undetected. 
TGFβR2 gene expression was down-regulated 1.5 folds following treatment with TGFβ2; 
in contrast, TGFβR3 gene expression was down-regulated more than two-fold (Figure 4.9). 
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Of the three bone morphogenic protein (BMP) receptors detected in pterygial fibroblasts 
BMPR2 had the highest value for baseline signal expression. The gene expression of all 
three BMP receptors remained unchanged following treatment with TGFβ2. Four 
fibroblast growth factor (FGF) receptors were detected in pterygial fibroblasts. All FGF 
receptors demonstrated a very low value for baseline signal expression (Figure 4.9). The 
gene expression of the four FGF receptors remained unchanged following treatment with 
TGFβ2 (Figure 4.9). Amongst epidermal growth factor (EGF) receptors family members, 
ERBB2 was detected slightly higher baseline signal value in pterygial fibroblasts while 
EGFR, ERBB3 and ERBB4 illustrated low baseline signal value (Figure 4.9). Three EGF 
receptors expressed in pterygial cells, ERBB2 was negatively affected by TGFβ2 treatment 
more than 1.5 fold (Figure 4.9).  
 
TGFβ isoforms 1, 2, and 3 were detected in pterygial cells. However, the baseline signal of 
TGFβ1 was relatively low value (Figure 4.9). TGFβ2 and TGFβ3 gene expressions were 
up-regulated more than 1.3 fold following addition of TGFβ2. In contrast, the gene 
expression of TGFβ1 was unchanged (Figure 4.9). Connective tissue growth factor (CTGF) 
was detected in pterygial fibroblasts with a high baseline signal value (Figure 4.9) and was 
up-regulated by more than two fold following treatment with TGFβ2 (Figure 4.9). Ten 
BMP isoforms on the microarray were all detected in pterygial fibroblasts and BMP1, 2, 3 
and 6 showed relatively higher baseline than others. Treatment of pterygial fibroblasts 
with TGFβ2 up-regulated BMP6 gene expression by 2 fold and down-regulated BMP4 
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gene expression more than 1.5 fold. The gene expression of all other BMPs detected 
remained unchanged following TGFβ2 treatment. In FGFs family, only FGF2 had a 
relatively higher baseline signal value and was up-regulated more than 1.5 fold following 
treatment with TGFβ2. The growth factors, EGF and HB-EGF (heparin binding-EGF), were 
detected in pterygial fibroblasts but the values were low. The gene expression of HB-EGF 
was up-regulated more than one and half fold following treatment with TGFβ2. In 
contrast, EGF gene expression was unchanged by TGFβ2 treatment. 
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Figure 4.9. A gene expression profile of growth factors and their selected receptors in 
pterygial fibroblasts. The data are presented in a colorimetric form to indicate the 
relative level of signal detected for each gene in non-stimulated serum-free controls 
using microarrays. Fold changes were detected in gene expression following 24 hours 
culture in 1ng/ml TGFβ2 relative to serum-free controls. Data are derived from the mean 
value of 4 separate experiments. 
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4.2.4.3 Gene expression profile of signalling components in pterygial 
fibroblasts 
All eight Smad family members present on the microarray, Smad1, 2 and 9 showed 
detectable but low baseline signal values. Smad3, 4, 5 and 6 had relatively high baseline 
signal values and Smad3 showed the highest signal value compared with others (Figure 
4.10). Smad7 gene expression was up-regulated by 1.5 fold and Smad3 and 6 were 
down-regulated by 2 fold and 1.5 fold following treatment with TGFβ2 (Figure 4.10). The 
gene expression of all other Smads detected remained unchanged following TGFβ2 
treatment. Both TNF receptor-associated protein (TRAP-1) and SMURF were detected in 
pterygial fibroblasts and had high baseline signal values (Figure 4.10). But with TGFβ2 
treatment, both TRAP-1 and SMURF gene expression were unchanged (Figure 4.11). 12 
MAPK family members were present and gave varying baseline signal values with MAPK6 
and 9 having higher signal values than others. MAPK6 gene expression was up-regulated 
1.5 fold following treatment with TGFβ2 (Figure 4.10). The gene expressions of all other 
MAPK members remained unchanged following TGFβ2 treatment. Inhibitors of FGF 
signalling, SPRY1 (sprouty 1), SPRY2 and were detected in pterygial cells and the baseline 
signal of was slightly higher. SPRY1 gene expression was down-regulated 1.5 fold by 
TGFβ2 but nothing change of SPRY2 gene expression by TGFβ2 (Figure 4.10). 
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Figure 4.10. A gene expression profile of signalling components in pterygial fibroblasts.  
The data are presented in a colorimetric form to indicate the relative level of signal 
detected for each gene in non-stimulated serum-free controls using microarrays. Fold 
changes were detected in gene expression following 24 hours culture in 1ng/ml TGFβ2 
relative to serum-free controls. Data are derived from the mean value of 4 separate 
experiments. 
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4.2.4.4 Gene expression profile of matrix components in pterygial 
fibroblasts 
33 collagens showed varying baseline signal values that collagen 1α1 (COL1A1) and 
collagen 1α2 (COL1A2) had the highest signal values. In addition, collagen 4α1 (COL4A1), 
collagen 5α1 (COL5A1), collagen 6α1 (COL6A1) and collagen 6α3 (COL6A3) showed 
relatively high baseline values. With respect to TGFβ2 treatment, the gene expression of 
7 collagens were up-regulated significantly that collagen 4α1 (COL4A1), collagen 4α2 
(COL4A2) and collagen 7α1 (COL7A1) were up-regulated 2 fold (Figure 4.11). The gene 
expression of collagens 4α5, 6α1, 6α2, 12α1, 15α1 and 18α1 were down-regulated by 1.5 
fold following TGFβ2 treatment. The gene expression of all other detected collagens 
remained unchanged following TGFβ2 treatment. Fibronectin was detected in pterygial 
fibroblasts with a relatively high baseline signal value (Figure 4.11). But with TGFβ2 
treatment, fibronectin gene expression was up-regulated 1.3 fold (Figure 4.11). Of 11 
laminin family members present on the microarray, the laminin members showed varying 
baseline signal values that LAMA4, LAMB1 and LAMB2 had higher baseline value. Only 
laminin γ1 (LAMC1) gene expression was up-regulated more than two-fold following 
treatment with both TGFβ2 (Figure 4.11). Moreover, the gene expressions of Laminin α2 
to 5 (LAMA), laminin β1 and 2 (LAMB) were down-regulated by at least 1.3 fold following 
treatment with TGFβ2, The gene expression of all other detected laminins remained 
unchanged following TGFβ2 treatment. 
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Figure 4.11. A gene expression profile of matrix components in pterygial fibroblasts. The 
data are presented in a colorimetric form to indicate the relative level of signal detected 
for each gene in non-stimulated serum-free controls using microarrays. Fold changes 
were detected in gene expression following 24 hours culture in 1ng/ml TGFβ2 relative to 
serum-free controls. Data are derived from the mean value of 4 separate experiments. 
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4.2.4.5 Gene expression profile of integrins in pterygial fibroblasts 
Of 28 integrins present on the microarray, of 15 integrins baseline signal values were 
detected in pterygial fibroblasts (Figure 4.12). The integrins showed varying baseline 
signal values with ITGAV, integrin β5 having high baseline signal values while value of 
integrin β1 was the highest. With respect to TGFβ2 treatment, the gene expressions of 
integrins α2 and α5 and β5 were up-regulated 1.5 fold while integrins α1 and α11 and αV 
were up-regulated 2 fold. However, integrins α8 was down-regulated 1.5 fold by TGFβ2 
(Figure 4.12). The gene expressions of the remaining 19 integrins were unchanged. 
 
4.2.4.7 Gene expression profile of myosin light chains and regulatory 
6enzymes in pterygial fibroblasts 
Gene expression profile of myosin light chains and regulatory enzymes in pterygial 
fibroblasts: seven myosin light chain family were detected on the microarray. These 
showed varying baseline signal values with MYL6 having highest baseline signal values 
whereas MYL1 to MYL4 had low baseline signal values (Figure 4.13). With respect to 
myosin regulatory enzymes, MYLK (also known as MLCK; myosin light chain kinase) were 
detected and gene expression of MYLK was up-regulated more than two-fold following 
the TGFβ2 treatment (Figure 4.13). Expression levels for other genes were unaffected by 
TGFβ2 treatment. 
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Figure 4.12. A gene expression profile of selected integrins in pterygial fibroblasts. The 
data are presented in a colorimetric form to indicate the relative level of signal detected 
for each gene in non-stimulated serum-free controls using microarrays. Fold changes 
were detected in gene expression following 24 hours culture in 1ng/ml TGFβ2 relative to 
serum-free controls. Data are derived from the mean value of 4 separate experiments. 
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4.13. A gene expression profile of myosin light chains and regulatory enzymes in pterygial 
fibroblasts. The data are presented in a colorimetric form to indicate the relative level of 
signal detected for each gene in non-stimulated serum-free controls using microarrays. 
Fold changes were detected in gene expression following 24 hours culture in 1ng/ml 
TGFβ2 relative to serum-free controls. Data are derived from the mean value of 4 
separate experiments. 
 
 
 
 
 
 
    
   
 
108 
 
4.3 Discussion 
TGFβ is a potent inducer of transdifferentiation throughout the body (Zavadil and 
Bottinger 2005). In the current study, TGFβ1 and TGFβ2 actively stimulated Smad2/3 
translocation into the nucleus of pterygial fibroblasts. Thus it demonstrates that active 
TGFβ1 and TGFβ2 receptors are present in pterygial fibroblasts. Cells showed a high 
degree of sensitivity to TGFβ1 and TGFβ2, such that low concentrations still induced 
Smad2/3 activation. The data support the notion that TGFβ2 is capable of significantly 
inducing transdifferentiation of pterygial fibroblasts to a myofibroblast which is a typical 
index of fibrosis. TGFβ2 significantly stimulated pterygial fibroblasts transdifferentiation 
while TGFβ1 did not activate the gene expression of αSMA, which is the potent marker of 
transdifferentiation and fibroblast contractility (Skalli, Pelte et al. 1989; Hinz, Celetta et al. 
2001). However, there was no significant change detected in the cells following the 
treatment of 10% serum for 24 hours. Validation of TGFβ/Smad signalling in relation to 
transdifferentiation in excised pterygial tissue also indicates its role in pterygial 
formation. 
 
Angiogenesis is considered a key process in the promotion of pterygium formation 
(Marcovich, Morad et al. 2002; Aspiotis, Tsanou et al. 2007). Proteome Profiler™ Array 
data revealed that pterygial-derived fibroblasts release angiogenic factors into the 
bathing medium with TGFβ2 exposure. It resulted in a significant increase in some well 
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documented angiogenic factors like IL-8, MMP9 and VEGF, endothelin-1 and fibroblast 
growth factor2 (Shoyab, Plowman et al. 1989; Ferrara and DavisSmyth 1997; Bergers, 
Brekken et al. 2000; Dunn, Heese et al. 2000; Fujiyama, Matsubara et al. 2001; Martin, 
Galisteo et al. 2009; Banerjee, Wu et al. 2012). It has been reported that the TGFβ2 
mediated MAPK pathway is involved in VEGF secretion in human retinal pigment 
epithelium (Bian, Elner et al. 2007) and TGFβ can also play an important role in VEGF 
mediated cell migration (Bulut, Pennartz et al. 2006). TGFβ is reported to induce VEGF 
production which leads to vascular remodelling and angiogenesis (Fang, Pentinmikko et 
al. 2012). A study suggested VEGF stimulates FGF-2 release but inhibits the expression of 
TGF-beta1 in injured endothelial cells (Li, Zhang et al. 2009). Interleukin 8 (IL8) is a 
pro-inflammatory cytokine which could contribute to pterygium (Di Girolamo, Kumar et 
al. 2002). It has been suggested that TGFβ can induce IL-8 production via a connective 
tissue grow factor independent pathway (Qi, Chen et al. 2006) and regulate IL8 mRNA 
and protein expression (Kumar, Rabadi et al. 1996), but TGFβ1 can also inhibit the 
IL-8-dependent pathway to play anti-inflammatory role (Smith, Noack et al. 1996). 
MMP-9 has been proposed to play a role in the progression of pterygium (Naib-Majani, 
Eltohami et al. 2004; Yang, Lin et al. 2009). It was reported that TGFβ1 can promote 
MMP9 expression through Smad3 recruitment (Chou, Wang et al. 2006) and TGFβ/Smad3 
signalling may play an important role in MMP9 transcription (Warburton, Shi et al. 2013). 
Another study reported that TGFβ can also increase MMP9 release via the p38 MAPK 
signalling pathway (Safina, Vendette et al. 2005). In addition, it has been reported that 
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TGFβ1 and 2 may regulate endothelin-1 synthesis and induce its secretion (Schnermann, 
Zhu et al. 1996). It is suggested that FGF2 induces transdifferentiation of retinal pigment 
epithelium cells by activation of MAPK/ERK kinase pathway (Susaki and Chiba 2007) and 
synergy of FGF2 and TGFβ could activate human corneal endothelial cells proliferation 
(Rieck, Oliver et al. 1995). Interestingly, with respect to anti-angiogenic factors, TGFβ2 
also significantly elevates the levels of angiostatin, thrombospondin-2 and Platelet Factor 
4. The overall potential to undergo angiogenesis is established by the net balance of 
various pro-angiogenic and anti-angiogenic factors (Pepper 1997). In the situation that 
excessive angiogenic factors are produced, anti-angiogenic factors may also be produced 
to neutralize these angiogenic factors.  
 
Pterygial fibroblasts express a range of growth factors including members of the TGFβ, 
CTGF, BMP, FGF, and EGF family and their corresponding receptors, all of them 
potentially play important roles in the progression of pterygium (Kria, Ohira et al. 1998; 
Nakagami, Murakami et al. 1999; Nolan, DiGirolamo et al. 2003; van Setten, Aspiotis et al. 
2003; Bianchi, Scarinci et al. 2012). TGFβ isoforms 1, 2, and 3 were detected in pterygial 
fibroblasts. Both TGFβR1 and TGFβR3 are essential for TGFβ2 signalling, the cells could 
not respond to TGFβ without their involvement (Massague 2000). Surprisingly, both 
TGFβR2 and TGFβR3 were down-regulated by TGFβ2. TGFβ2 and TGFβ3 gene expressions 
were up-regulated following treatment with TGFβ2 while the gene expression of TGFβ1 
was unchanged. Connective tissue growth factor (CTGF) showed very high baseline signal 
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value and was up-regulated 2 fold following treatment with TGFβ2. It has been reported 
that CTGF can give rise to fibrosis in the epithelium of pterygium (van Setten, Aspiotis et 
al. 2003). CTGF actives the TGFβ/Smad signalling pathway by suppressing Smad7, the 
antagonist, of Smad2/3 signalling (Wahab, Weston et al. 2005). TGFβ2 up-regulated gene 
expression of BMP6 and down-regulated BMP4. Bone morphogenetic proteins (BMPs) 
belong to transforming growth factor beta family; they could play various biological 
functions as cell proliferation, apoptosis, and differentiation in human organs and tissues 
including eye (Hogan 1996; Massague 1998). It was reported that BMP6 is detected 
significantly increased in scar conjunctival tissue compared with normal conjunctiva and 
it may play a role in conjunctival tissue fibrosis and wound healing process (Andreev, 
Zenkel et al. 2006). TGFβ/ BMP signalling pathways were activated by either Smad 
dependent or p38 MAPK pathway to regulate cellular functions (Chen, Deng et al. 2012). 
Therefore, TGFβ/ BMP signalling pathways in pterygium may play a similar role in tissue 
fibrosis. In the members of FGF family of growth factors and receptors observed in 
pterygial fibroblasts, only FGF2 was detected with a relatively high signal value, and gene 
expression was up-regulated by TGFβ2. A previous study detected the combination of 
FGF2 and TGFβ could enhance the stimulation of human corneal endothelial cells 
proliferation (Rieck, Oliver et al. 1995). FGF2 plays an important role in cell proliferation 
and interaction of TGFβ with FGF2 is reported to influence cell differentiation (He, Yu et 
al. 2008). FGF2 can induce TGFβ, but reduces collagen1 secretion and may play a 
negative feedback mechanism in cell differentiation and ECM accumulation (Unda, 
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Martin et al. 2000; Cross, Reid et al. 2006). With respect to growth factors EGF and 
HB-EGF (heparin binding-EGF), they were detected with a low expression in pterygial 
fibroblasts. However, TGFβ2 increased HB-EGF gene expression and interestingly, the 
receptor ERBB2 was down-regulated by TGFβ2. It was reported that Heparin binding 
EGF-like growth factor can stimulate smooth muscle cell migration (Higashiyama, 
Abraham et al. 1993). It was reported that both TGFβ1 and 2 can stimulate production of 
HB-EGF during airway epithelial repair (Ito, Harada et al. 2011).   
 
Moreover, the signal transduction and regulation molecules of TGFβ, Smad family were 
investigated. All members of the Smad family and their associated components (TRAP-1, 
smurf) were expressed in pterygial cells. Moreover, the active signalling was detectable in 
response to TGFβ. As the major inhibitory regulator of TGFβ/Smads signalling, Smad7 was 
expressed with a high signal value in pterygial cells and was up-regulated by TGFβ2. The 
essential signalling Smads 3, 4 showed a relatively high level of expression in the cells. 
Smads2, 3 and 4 mediated TGFβ signals, the Smad2/3-Smad4 complex can translocate 
into the nucleus to play a role in transcriptional functions (Massague 1998). Smad7 is a 
major antagonist of TGFβ signalling and blocks Smad2/3 phosphorylation (Nakao, 
Afrakhte et al. 1997). Mitogen-activated protein kinases signalling family, which includes 
ERK1 (MAPK3), JNK (MAPK8) and p38 (MAPK14) were investigated in pterygial fibroblasts. 
In recent research, the active MAPKs signalling pathway was identified in pterygium 
(Torres, Enriquez-de-Salamanca et al. 2011). It may function as the mediator in TGFβ 
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signalling transduction (Yamaguchi, Shirakabe et al. 1995). The MAPK members detected 
varying baseline signal values with MAPK6 and 9 having relatively high level. MAPK6 gene 
expression was up-regulated following treatment with TGFβ2 and SPRY1 was 
down-regulated by TGFβ2. Inhibition of MAPKs signalling can abolish the UVB-induced 
angiogenic factors release IL6, IL8 and VEGF in pterygial cells (Di Girolamo, Wakefield et 
al. 2006). MAPK6 is a marker of BRAF-induced oncogenic signalling to affect cell 
proliferation and angiogenesis in melanoma (Hoeflich, Eby et al. 2006). SPRY1 is the 
Inhibitor of FGF signalling (Hanafusa, Torii et al. 2002). TGFβ2 suppressed SPRY1 
expression may induce FGF signalling and thus impact TGFβ transduction in pterygial 
fibroblasts. It has been reported that both MAPK and Smad pathways are involved in 
TGFβ activities and imbalance of them may induce TGFβ tumour promoting effects 
(Nickl-Jockschat, Arslan et al. 2007). The p38 MAPK inhibitor can block TGFβ Smad 
signalling (Fu, O'Connor et al. 2003) and the synergistic activation of Smad and MAPK 
pathways can induce excess collagen deposition (Tsukada, Westwick et al. 2005) and 
regulate cell differentiation via TGFβ (Akel, Bertolette et al. 2003). 
 
Extracellular matrix provides structural support between cells and stimulates the 
remodelling process, inflammation, and angiogenesis to result in progression of 
pterygium (Di Girolamo, Chui et al. 2004; Naib-Majani, Eltohami et al. 2004). All of 33 
collagens were detected in pterygial fibroblasts. The collagen 1α1, collagen 4α1, collagen 
5α1, collagen 6α1 and collagen 6α3 and collagen 1α2 demonstrated very high signal. The 
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collagen 4α1 and 2 were highly up-regulated by TGFβ2. Collagen 4 was strongly positive 
in the wall of pterygial blood vessels (Naib-Majani, Eltohami et al. 2004). TGFβ2 also 
activated the Collagen 1α1, 5α1, 7α1, 8α2 and 10α1 gene expression. Collagen I is 
involved myofibroblasts synthesis in fibrocontractive disease (Gabbiani 2003). As the 
main component of connective tissue, the other positively regulated collagens may also 
be involved in pterygial tissue fibrosis. In addition, with respect to laminin family 
members, TGFβ2 could up regulate laminin γ1 gene expression. As a noncollagenous 
glycoprotein from basement membrane, laminins family can interact with collagens to 
generate extracellular matrix (Kefalides 1973; Timpl, Rohde et al. 1979). Laminins have 
previously been reported to be highly expressed in pterygial vascular walls (Naib-Majani, 
Eltohami et al. 2004). 
 
The gene expression of the members of integrin family was detected in pterygial 
fibroblasts. An integrin is a cell surface receptor mediate the cell attachment, it is a 
primary mediator of the extracellular matrix that pass chemical and mechanical signals 
into the cells (Giancotti and Ruoslahti 1999). It plays many important roles in cell 
physiology like cell motility and cell cycle (Clark and Brugge 1995; Giancotti and Ruoslahti 
1999). In present study, Integrin β1 and Integrin β5 expressed relatively high signal level 
in pterygial fibroblasts. It is reported that Integrin β1 transmits mechanical signals to the 
cytoskeleton and produce a stiffening response which correlates with focal adhesion 
formation (Wang, Butler et al. 1993). Various integrins including α1, α5, αV and β5 were 
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up-regulated by TGFβ2. Integrins consist of 16α and 8β transmembrane subunits and β1 
associate with 12 α integrin subunits (Clark and Brugge 1995; Elner and Elner 1996). 
Therefore, αVβ5 and α5β1 integrins may demonstrate high levels of expression by TGFβ2 
stimulation in pterygial fibroblasts. It has been reported that integrin signalling is 
involved in TGFβ induced myofibroblast differentiation (Jester, Huang et al. 2002). Many 
integrin β subunits can form heterodimers with αV like αVβ5 and αVβ1 (Walker and 
Menko 2009). It reported that αVβ5 plays a critical role in growth of blood vessels and 
potentiate angiogenic pathways in ocular angiogenesis (Friedlander, Brooks et al. 1995). 
TGFβ2 is also reported to induce αVβ5 gene expression in lens epithelial cell line (Dawes, 
Elliott et al. 2007). αV integrins may play an important role in mediating the matrix 
proteins through activation of TGFβ in lens fibrotic diseases (Walker and Menko 2009). It 
is proposed that α5β1 may regulate the interaction between myofibroblast and 
fibronectin (Hakkinen, Heino et al. 1994). Gene expression of light chains kinase (MYLK) 
and regulatory enzymes in pterygial fibroblasts were investigated. MYLK was 
up-regulated more than two-fold by TGFβ2. MYLK is involved in mechanism of regulating 
smooth muscle contraction via calcium/calmodulin-dependent myosin light chain 
phosphorylation (Lazar and Garcia 1999). 
 
The current study investigated TGFβ2 induced signalling pathway, transdifferentiation, 
angiogenesis and matrix contraction processes. TGFβ2/Smad signalling is present in 
pterygial fibroblasts and TGFβ2 can significantly promote gene expression of αSMA which 
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is an indicative marker of transdifferentiation. The gene microarrays and Proteome 
Profiler identified potentially important genes and secreted proteins following 
application of TGFβ2, which may contribute pathological process in pterygium.  
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CHAPTER 5 
Summary and future work 
 
Pterygium is a proliferative fibrovascular altered conjunctival tissue. Cell proliferation, 
fibrosis and angiogenesis are the major features of pterygium. Thus, the primary 
objective of the current thesis was to determine the influences of serum (mimic the 
blood supply) and TGFβ on cellular proliferation, signalling, transdifferentiation and 
angiogenesis in pterygial fibroblasts. These processes are likely to contribute to the 
progression of this disease (Cameron 1983; Karukonda, Thompson et al. 1995; 
Coroneo, Di Girolamo et al. 1999; Marcovich, Morad et al. 2002; Aspiotis, Tsanou et 
al. 2007). In the laboratory, pure pterygial fibroblast cultures were successfully 
established from donor pterygium specimens and assessed. Through histological and 
immunochemical techniques, it was confirmed that pterygium was more compact 
arrangement of fibroblasts, which demonstrate elevated levels of transdifferentiation 
markers and more abundant blood vessels relative to normal conjunctiva. Serum 
supplemented media was commonly used for the cell and tissue culture and the 
serum may be one of the major environmental factors for pterygium because of the 
high degree of vasculature associated with this disorder. Serum angiogenic activity 
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was previously reported in inflammatory diseases (Zielonka, Demkow et al. 2007; 
Zielonka, Demkow et al. 2007). The extensive vascular network is likely to 
significantly contribute to the progression of the disease. An approach adopted in the 
current study to understand the role a rich blood supply can perform on pterygial cell 
behaviour was to maintain cells in a serum rich and serum poor/starved environment. 
This provides a simple model that generates extreme conditions and allows changes 
that result to be assessed. As predicted pterygial cells are reliant on a supply of 
growth and survival factors from serum. Little work has been carried out on pterygial 
cells with regard to calcium signalling and thus increasing our knowledge of this 
fundamental signalling mechanism was important. Histamine and epidermal growth 
factor have been shown to stimulate intracellular calcium mobilization in pterygial 
derived fibroblasts (Maini, Collison et al. 2002). However, the mechanisms regulating 
calcium signalling and its functional importance have not been fully resolved. In 
current study, serum deprivation suppressed histamine, ATP, acetylcholine and 
epidermal growth factor mediated calcium signalling in pterygial fibroblast. It 
demonstrates that these receptors are functional available on the surface of 
fibroblasts derived from human pterygium. All ligands (histamine, ATP, EGF, 
acetylcholine) provoke a reduced calcium response in serum deprivation conditions, 
which suggests that a common factor is changing. Therefore, Illumina gene array was 
used here to establish profiles of these receptors associated with the test ligands and 
calcium signalling components. However, maintenance in 10% serum did not elevate 
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gene expression of histaminergic, purinergic, cholinergic and EGF receptors or 
activate any important calcium signalling components relative to serum starved cells. 
To address the importance of the ER store, intracellular Ca2+ pump inhibitor 
thapsigargin was used to observe ER store depletion which increases intracellular 
Ca2+ without generating IP3 (Parekh and Penner 1997). In the present study, addition 
of thapsigargin to cells incubated in serum free condition can deplete the calcium 
store relative to serum maintained cells. Therefore, intracellular calcium stores are 
sensitive to serum deprivation. Many studies have reported disruption of the ER 
calcium have influence on cell division (Wang, Wormstone et al. 2005) and migration 
(Duncan, Wormstone et al. 1997; Nicola, Timoshenko et al. 2005). Persistent 
depletion of the calcium store play significant role in reducing cell survival, migration, 
protein synthesis, ER stress and potentially cell death by apoptosis (Shi, Wang et al. ; 
Nicola, Timoshenko et al. 2005; Wang, Wormstone et al. 2005; Zhang, Duncan et al. 
2007). Therefore, serum starvation suppressed calcium signalling could affect 
functions related to the pterygium. Further investigation of these ligands mediated 
signalling pathways, their functional roles in pterygium and the effects of long-term 
depletion of the ER store and ER stress related events in cell growth and migration of 
pterygial fibroblasts will be a valuable topic of investigation.  
 
Investigation of serum versus serum-free responses provides gross changes that are 
of interest to pterygial cells. A second line of study was to concentrate on one specific 
                    
           
 
120 
 
pathway and identify its potential in regulating pterygium formation. As pterygium 
was reported to possess the hallmarks of fibrosis (Coroneo, Di Girolamo et al. 1999), 
TGFβ was investigated, as this is strongly implicated in fibrotic disorders (Leask and 
Abraham 2004). Serum contains various growth factors and TGFβ is likely to be 
present (in a latent or active form) at some level. With regard to pterygium 
pathologies, serum can produce/release pro-angiogenic factors to induce angiogenic 
activities in inflammatory disease (Zielonka, Demkow et al. 2007; Zielonka, Demkow 
et al. 2007). TGFβ can also play an important role in transdifferentiation and 
regulation of the extracellular matrix (Miettinen, Ebner et al. 1994). The most potent 
marker of myofibroblast in transdifferentiation is αSMA (Desmouliere, Geinoz et al. 
1993). Myofibroblasts synthesize extracellular matrix components to play a role in 
wound healing and fibrocontractive diseases (Gabbiani 2003). The current work 
demonstrated that active TGFβ1 and TGFβ2 receptors are detected and showed high 
sensitivities in pterygial fibroblasts. TGFβ2 was capable of significantly inducing 
transdifferentiation of pterygial fibroblasts to a myofibroblast at the gene level. The 
data supported that TGFβ2 is a more potent isoform in the promotion of 
transdifferentiation in the superficial ocular tissues and human aqueous humour 
(Jampel, Roche et al. 1990; Pasquale, Dormanpease et al. 1993). 10% serum and 
TGFβ2 stimulated conditions were highlighted to provide a global profile of gene 
expression in pterygial fibroblasts. TGFβ has been reported to promote 
transdifferentiation and regulate extracellular matrix modification in mammary 
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epithelial cells (Miettinen, Ebner et al. 1994), lens capsular bag (Wormstone, Tamiya 
et al. 2002) and human Tenon’s fibroblasts (Meyer-Ter-Vehn, Katzenberger et al. 
2008).  
 
A range of growth factors including TGFβ, CTGF, BMP, FGF, and EGF family and their 
corresponding receptors were investigated in microarray analysis. They were 
reported to potentially involve in pterygium progression (Kria, Ohira et al. 1998; 
Nakagami, Murakami et al. 1999; Nolan, DiGirolamo et al. 2003; van Setten, Aspiotis 
et al. 2003; Bianchi, Scarinci et al. 2012). The important finding from the investigation 
is that connective tissue growth factor (CTGF) showed high expression in pterygial 
fibroblasts in non-treated condition and was up-regulated following treatment with 
TGFβ2. CTGF is present in epithelium of pterygium and possibly interact with vascular 
growth factor (VEGF) to contribute to fibrosis in pterygium (van Setten, Aspiotis et al. 
2003). It has been reported that CTGF enhances phosphorylation and nuclear 
translocation of Smad 2/3 and activates TGFβ/Smad signalling pathway by 
suppressing Smad7 (Wahab, Weston et al. 2005). The Smad proteins are essential  
intracellular effectors of TGFβ/Smad signalling to regulate transcription events in 
nucleus (Derynck, Zhang et al. 1998). Interestingly, in current study TGFβ2 
significantly enhanced Smad7 gene expression, this may explain the reason why 
TGFβ2 down-regulated the essential signalling component Smad3. TGFβ2 also 
down-regulated the antagonist of TGFβ signalling Smad6 (Imamura, Takase et al. 
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1997). This thus demonstrates that following treatment with TGFβ2, Smad6 was 
suppressed to activate signalling and Smad7 may participate in a negative feedback 
mechanism in pterygial fibroblasts. The interaction in Smad proteins to keep balance 
in signalling needs further investigation. All three isoforms of TGFβ and their 
receptors were detectable in pterygial fibroblast. This suggests an active TGF/Smad 
signalling pathway is in place in pterygial fibroblasts. The immunochemical data also 
supports this issue. Although TGFβ2 and TGFβ3 receptors were negatively regulated 
by TGFβ2 and TGFβR3 expression were down-regulated following 10% serum 
treatment. TGFβR2 and 3 complex was reported indispensable in TGFβ signalling 
(Brown, Boyer et al. 1999). Therefore, high levels of TGFβ2 may play an inhibitory 
role on TGFβR2 and 3 receptor expressions. The suppressed TGFβR3 response by 
TGFβ2 was also found in lens cells (Dawes, Elliott et al. 2007). TGFβ2, 3 and bone 
morphogenetic protein 6 (BMP6) were up-regulated by TGFβ2. It demonstrates that 
TGFβ2 in high level could persistently increase the overall pool of TGFβ2 in pterygial 
fibroblasts. Basic fibroblast growth factor (FGF2) showed relatively high level of gene 
expression and was up-regulated by TGFβ2. Previous studies showed bFGF expressed 
high level in the cultured fibroblasts derived from primary and recurrent pterygium 
(Kria, Ohira et al. 1998; Detorakis, Zaravinos et al. 2010). It has been reported that 
synergy of FGF2 and TGFβ could activate human corneal endothelial cells 
proliferation (Rieck, Oliver et al. 1995) and FGF2 induces transdifferentiation of 
retinal pigment epithelium cells through MAPK/ERK signalling pathway (Susaki and 
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Chiba 2007). MAPK signalling family include ERK1 (MAPK3), JNK (MAPK8) and p38 
(MAPK14) were detected in pterygial fibroblasts and TGFβ2 up-regulated MAPK6 
gene expression in pterygial fibroblasts. MAPK6 was reported to play a role in cell 
proliferation and angiogenesis in tumour cells (Hoeflich, Eby et al. 2006). The active 
MAPKs signalling was identified in pterygium (Torres, Enriquez-de-Salamanca et al. 
2011) and it reported ERK1/2 MAPK dependant pathway was involved in ultraviolet 
light induced MMP1 expression in development of pterygium (Di Girolamo, Coroneo 
et al. 2003). MAPK signalling play a role on mediating TGFβ signalling transduction 
(Yamaguchi, Shirakabe et al. 1995). It has been reported that synergy of MAPK and 
Smad pathways involve TGFβ activities (Nickl-Jockschat, Arslan et al. 2007). They 
induces excess collagen deposition (Tsukada, Westwick et al. 2005) and regulates cell 
differentiation via TGFβ (Akel, Bertolette et al. 2003). In addition, SPRY1 is negatively 
mediated by TGFβ2. It is the Inhibitor of FGF signalling (Hanafusa, Torii et al. 2002). 
TGFβ2 suppressed MAPK inhibitory pathway may stimulate FGF signalling via 
ERK/MAPK pathway and induce TGFβ signalling in pterygial fibroblasts. The functional 
role of MAPK in pterygium could be a target in future study. 
 
Extracellular matrix (ECM) constitutes the connective tissues filling the extracellular 
space. Overexpression of ECM with alteration of the collagen and elastic fibres are 
contributing factors to pterygium pathological progression (Cameron 1983; 
Karukonda, Thompson et al. 1995; Coroneo, Di Girolamo et al. 1999). TGFβ2 can 
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up-regulate gene expression of collagen 4 which was positively distributed in 
pterygial vascular walls (Naib-Majani, Eltohami et al. 2004). Another important 
finding is that TGFβ2 enhanced collagen 1 gene expression which was reported to 
play a role in myofibroblasts synthesis in wound healing and fibrocontractive disease 
(Gabbiani 2003). TGFβ2 can also simulate main component of connective tissue 
laminin γ1 gene expression in pterygial fibroblasts. It has been reported that laminins 
may interact with collagens to generate extracellular matrix in pterygium 
(Naib-Majani, Eltohami et al. 2004). Moreover, a number of cell surface receptor 
integrin family members were stimulated by TGFβ2. Integrin may transduct signals 
into pterygial fibroblasts to induce ECM remodelling to contribute 
transdifferentiation in pterygium. It reported that the synergy of integrin and TGFβ2 
may induce transdifferentiation in rabbit keratocytes (Jester, Huang et al. 2002). The 
data demonstrates Integrin β1 is most abundant in pterygial fibroblasts and it was 
reported that Integrin β1 can associate with any 1 of 10 α subunits to form α-β1 to 
bind ECM ligands (Clark and Brugge 1995; Elner and Elner 1996). Integrin α1, α5, αV 
and β5 were up-regulated by TGFβ2. Therefore, α5β1, αVβ5 integrin combinations 
may demonstrate higher expression as a consequence of TGFβ2 stimulation in 
pterygial fibroblasts. Integrin signalling is involved in myofibroblast differentiation via 
TGFβ activities (Jester, Huang et al. 2002). Integrin α5β1 is the receptor of fibronectin 
and it regulates the interaction between myofibroblast and fibronectin (Hakkinen, 
Heino et al. 1994) and may also play a role in ocular angiogenesis and tumour 
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progression (Danen, Tenberge et al. 1994; Muether, Dell et al. 2007). TGFβ2 induces 
αVβ5 gene expression in lens fibrotic diseases (Dawes, Elliott et al. 2007; Walker and 
Menko 2009) and it is feasible that αVβ5 could also play a role in pterygium. αVβ5 
may also regulate new growth of blood vessels and potentiate ocular angiogenesis 
(Friedlander, Brooks et al. 1995). In addition, TGFβ2 also up-regulated MYLK which 
involved in regulation of smooth muscle contraction (Lazar and Garcia 1999).  
 
Pterygium exhibits a high degree of vasculature relative to normal conjunctiva. 
Angiogenesis plays an important role in promoting pterygium formation (Marcovich, 
Morad et al. 2002; Aspiotis, Tsanou et al. 2007). Proteome profiler™ array, data 
showed that pterygial-derived fibroblasts released angiogenic factors into the 
bathing medium. A number of important pro-angiogenic factors showed high protein 
expression in 10% serum and TGFβ2 bathing medium. The important findings include 
IL-8, MMP9, VEGF were positively mediated by both 10% serum and TGFβ2 
conditions in pterygial fibroblasts. This suggests potent angiogenic activities in 
pterygial fibroblasts and supports the work of previous studies (Di Girolamo, Kumar 
et al. 2002; Marcovich, Morad et al. 2002; Reid and Dushku 2010; Liang, Jiang et al. 
2012). The active involvement of these pro-angiogenic factors may increase cell 
migration and promoting the formation of blood vessels in the pathogenesis of 
pterygium (Salcedo, Ponce et al. 2000; Low, Drugea et al. 2001; Ma, Wang et al. 
2007). The data demonstrated that pterygial fibroblasts growing in the presence of a 
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rich blood supply and TGFβ may release VEGF, FGF2, MMP9, IL8 and EN1 
pro-angiogenic factors to support pterygial fibroblast cellular angiogenic activities. In 
addition, angiogenesis is controlled by the net balance between positive and negative 
regulatory activity. 10% serum significantly suppressed the release of anti-angiogenic 
factors angiostatin, SerpinE1, TIMP-1 and Thrombospondin-1 (Murphy, Unsworth et 
al. 1993; Cao 2001). The inhibitory functions of these factors may reduce the 
progressive nature of pterygium. TGFβ2 activated production of angiostatin, 
Thrombospondin-2 and Platelet Factor 4. All these data illustrate that the synergy 
between positive and negative angiogenic activities are important in the mechanism 
of pterygial angiogenesis. Another interesting phenomenon is that serum starvation 
can also induce the angiogenesis by increasing the production/release of a number of 
angiogenic factors. This may be because cells in serum free conditions release 
angiogenic factors to promote new blood vessel formation and enrich their local 
environment. Hypoxia can activate hypoxia-inducible factor (HIF) to increase VEGF 
(Risau 1997; Pousa and Gisbert 2006). The hypoxia mediated angiogenesis with a 
number of angiogenic factors like FGF-2, IGFBP-1 and angiogenin were reported 
(Tazuke, Mazure et al. 1998; Hartmann, Kunz et al. 1999; Kroon, Koolwijk et al. 2001). 
However, due to the weak protein expression of these up-regulated angiogenic 
factors in serum starved condition, the Western blot will be utilized to address this 
issue in future study.  
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Fibroblasts derived from pterygium can be successfully cultured and analysed, 
post-mortem and biopsy tissue can be assessed to provide important data relating to 
the native tissue. Calcium activities play a role in pterygial fibroblast cellular functions. 
Cells were sensitive to serum starvation that resulted in reduced growth and 
impaired calcium signalling. The cells were found to be sensitive to the pro-fibrotic 
protein TGFβ, which induced Smad signalling and myofibroblast expression. TGFβ was 
found to induce transdifferentiation and elevate angiogenic factors in pterygial 
derived fibroblasts. TGFβ2 and serum levels/blood supply can play a key role in 
pterygial cell responses and on the pathogenesis and development of pterygium.  
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APPENDIX I 
Gene Microarray: 10% serum and TGFβ2 regulated gene expression 
data 
 
The following tables list all genes that are either up-regulated or down-regulated 
more than 2 fold in pterygial fibroblasts by 10% serum and TGFβ2 in four biological 
replicates detected by gene microarrays.   
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Appendix IA. Gene up-regulated more than 2 fold in pterygial fibroblasts by 10% serum  
 Symbol              Gene Fold change 
ID3 inhibitor of DNA binding 3 9.03 
RGS4 regulator of G-protein signalling 4 5.87 
ACTG2 actin, gamma 2, smooth muscle, enteric 5.6 
ID1 inhibitor of DNA binding 1 4.96 
CDC20 cell division cycle 20 homolog 4.03 
ACTC1 actin, alpha, cardiac muscle 1 3.86 
KRT7 keratin 7 3.53 
TUBB3 tubulin, beta 3 class III 3.43 
GLIPR1 GLI pathogenesis-related 1 3.19 
ATOH8 atonal homolog 8 (Drosophila) 3.13 
CEP55 centrosomal protein 55kD 3.12 
UBE2C ubiquitin-conjugating enzyme E2C 3.08 
CCNA2 cyclin A2 3.08 
ANLN anillin, actin binding protein 3.02 
AURKA aurora kinase A 3.02 
NEFM neurofilament, medium polypeptide 3.00 
PRC1 protein regulator of cytokinesis 1 3.00 
  SERPINE1 serpin peptidase inhibitor, clade E 2.99 
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CCNB2 cyclin B2 2.98 
  KRTAP1-5 keratin associated protein 1-5 2.96 
KRT34 keratin 34 2.92 
TK1 thymidine kinase 1, soluble 2.92 
PBK PDZ binding kinase 2.86 
TOP2A topoisomerase (DNA) II alpha 170kDa 2.85 
CDKN3 cyclin-dependent kinase inhibitor 3 2.77 
PTTG1 pituitary tumour-transforming 1 2.72 
KIFC1 kinesin family member C1 2.64 
KIF20A kinesin family member 20A 2.63 
DKK1 dickkopf 1 homolog (Xenopus laevis) 2.63 
CDCA8 cell division cycle associated 8 2.63 
HJURP Holliday junction recognition protein 2.61 
CKAP2L cytoskeleton associated protein 2-like 2.60 
AURKB aurora kinase B 2.60 
CDCA3 cell division cycle associated 3 2.52 
IL7R interleukin 7 receptor 2.51 
CKS2 CDC28 protein kinase regulatory subunit 2 2.49 
RRM2 ribonucleotide reductase M2 2.48 
DLGAP5 discs, large (Drosophila) homolog-associated protein 5 2.47 
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LOC651816 ubiquitin-conjugating enzyme E2S 2.47 
 TRIP13 thyroid hormone receptor interactor 13 2.46 
NCAPG non-SMC condensin I complex, subunit G 2.43 
COTL1 coactosin-like 1 (Dictyostelium) 2.40 
MELK Maternal embryonic leucine zipper kinase 2.40 
MALL mal, T-cell differentiation protein-like 2.39 
ODC1 ornithine decarboxylase 1 2.39 
CENPA centromere protein A 2.38 
PRR11 proline rich 11 2.37 
STS-1 UBASH3B Ubiquitin associated and SH3 domain containing B 2.34 
SPOCD1 SPOC domain containing 1 2.32 
TPM1 tropomyosin 1 (alpha) 2.32 
SPC24 Kinetochore protein Spc24 2.34 
LOC731049 similar to Ubiquitin-conjugating enzyme E2S 2.31 
NPAS1 
neuronal PAS domain protein 1 2.31 
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 2.31 
PTTG3P pituitary tumour-transforming 3, pseudogene 2.30 
BDKRB1 bradykinin receptor B1 2.30 
LOC92755 tubulin, beta pseudogene 1 2.28 
TACC3 transforming, acidic coiled-coil containing protein 3 2.28 
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CDCA2 cyclin-dependent kinase inhibitor 2A 2.26 
TYMS thymidylate synthetase 2.24 
ID2 inhibitor of DNA binding 2, 2.24 
CDC45L cell division cycle 45 2.23 
TNFRSF12A tumour necrosis factor receptor superfamily,  
member 12A 
2.23 
CENPN centromere protein N 2.22 
PDCD1LG2 programmed cell death 1 ligand 2 2.22 
ASPM asp (abnormal spindle) homolog, microcephaly  
associated (Drosophila) 
2.21 
F3 coagulation factor III (thromboplastin, tissue factor) 2.21 
TPX2 microtubule-associated, homolog (Xenopus laevis) 2.20 
UHRF1 ubiquitin-like with PHD and ring finger domains 1 2.18 
LOC730743 
similar to keratin associated protein 1-1 
2.18 
NUSAP1 nucleolar and spindle associated protein 1 2.18 
LOC731314 
similar to H2A histone family, member X 
2.17 
GTSE1 G-2 and S-phase expressed 1 2.17 
LOX lysyl oxidase 2.16 
LOC402221 actin, beta pseudogene 2.16 
RPS7 ribosomal protein S7 2.14 
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BIRC5 baculoviral IAP repeat containing 5 2.14 
CNN1 calponin 1, basic, smooth muscle 2.14 
LOC100133565 ubiquitin-like, containing PHD and RING finger domains, 1 
pseudogene 
2.13 
CDCA5 cell division cycle associated 5 2.12 
ELN Elastin 2.12 
RAD51AP1 RAD51 associated protein 1 2.11 
SKA1 spindle and kinetochore associated complex subunit 1 2.11 
LOC728255 keratin associated protein 1-4 2.10 
LOC728285 similar to keratin associated protein 2.08 
NEK7 NIMA-related kinase 7 2.07 
HS.579631 small ILF3/NF90-associated RNA A1 2.06 
TUBB6 tubulin, beta 6 class V 2.06 
RACGAP1 Rac GTPase activating protein 1 2.05 
FOSL1 FOS-like antigen 1 2.04 
KIF2C kinesin family member 2C 2.04 
DDX39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39A 2.04 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.02 
GINS2 GINS complex subunit 2 (Psf2 homolog) 2.01 
LPXN leupaxin 2.00 
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Appendix IB. Gene down-regulated more than 2 fold in pterygial fibroblasts by 10% serum 
Symbol              Gene Fold change 
TMEM119 transmembrane protein 119 
0.27 
SCD stearoyl-CoA desaturase (delta-9-desaturase) 0.31  
ADH1A alcohol dehydrogenase 1A (class I), alpha polypeptide 0.31 
RCAN2 regulator of calcineurin 2 0.32 
APOD apolipoprotein D 0.33 
EPHB6 EPH receptor B6 0.34 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 0.34 
TM7SF2 transmembrane 7 superfamily member 2 0.34 
RARRES3 retinoic acid receptor responder (tazarotene induced) 3 0.34 
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide 0.35 
SLC2A12 solute carrier family 2, member 12 0.36 
ANGPTL2 angiopoietin-like 2 0.36 
OLFML2A 
 
olfactomedin-like 2A 
0.37 
GAS1 growth arrest-specific 1 0.40 
LOC731954 unkown 
0.40 
CTSF cathepsin F 0.41 
TKT transketolase 0.41 
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 0.42 
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GPNMB glycoprotein (transmembrane) nmb 0.43 
SCARA5 Scavenger receptor class A member 5 0.43 
COLEC12 collectin sub-family member 12 0.43 
GSTM3 glutathione S-transferase mu 3 (brain) 0.43 
SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin  
domain containing 1 
0.44 
TGFBR3 transforming growth factor, beta receptor III 0.45 
QPRT quinolinate phosphoribosyltransferase 0.45 
HS.552087 slit homolog 3 (Drosophila) 0.45 
CTSK cathepsin K 0.45 
SVIL supervillin 0.46 
DHCR7 7-dehydrocholesterol reductase 0.46 
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) 0.46 
RAB7B RAB7B, member RAS oncogene family 0.47 
PLSCR4 phospholipid scramblase 4 0.47 
TSHZ2 teashirt zinc finger homeobox 2 0.47 
INSIG1 insulin induced gene 1 0.47 
LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 0.47 
PAMR1 peptidase domain containing associated with muscle 
regeneration 1 
0.48 
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LDLR low density lipoprotein receptor 0.48 
C13ORF15 Regulator of cell cycle RGCC 0.48 
C1S complement component 1, s subcomponent 0.48 
PCYOX1 prenylcysteine oxidase 1 0.48 
LRP1 low density lipoprotein receptor-related protein 1 0.48 
CMBL carboxymethylenebutenolidase homolog (Pseudomonas) 0.49 
HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent) 0.49 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 0.49 
PTGES prostaglandin E synthase 0.49 
SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 0.49 
MXRA5 matrix-remodelling associated 5 0.50 
GSTM5 glutathione S-transferase mu 5 0.50 
MGP matrix Gla protein 0.50 
AKR1C3 aldo-keto reductase family 1, member C3 0.50 
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Appendix IC. Gene up-regulated more than 2 fold in pterygial fibroblasts by TGFβ2   
Symbol                Gene Fold change 
ACTC1 actin, alpha, cardiac muscle 1   10.37 
ID3 inhibitor of DNA binding 3, dominant negative  
helix-loop-helix protein 
   8.38 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen  
activator inhibitor type 1), member 1 
   7.81 
C5ORF13 neuronal regeneration related protein homolog (rat)    7.24 
ACTG2 actin, gamma 2, smooth muscle, enteric    6.93 
MAMDC2 MAM domain containing 2 6.84 
IER3 immediate early response 3    6.19 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 5.59 
IL11 interleukin 11 5.57 
COL4A1 collagen, type IV, alpha 1 4.91 
RGS4 regulator of G-protein signalling 4 4.87 
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 4.84 
CNN1 calponin 1, basic, smooth muscle 4.63 
HS.36053 neuronal regeneration related protein homolog (rat) 4.63 
ANKRD38 
KANK4 
KN motif and ankyrin repeat domains 4 4.51 
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BMP6 bone morphogenetic protein 6 4.47 
TPM1 tropomyosin 1 (alpha) 4.42 
KANK4 KN motif and ankyrin repeat domains 4 4.41 
TMEM2 transmembrane protein 2 4.38 
DACT1 dapper, antagonist of beta-catenin, homolog 1 
 (Xenopus laevis) 
4.32 
ADAM19 ADAM metallopeptidase domain 19 4.24 
FSTL3 follistatin-like 3 (secreted glycoprotein) 4.15 
TP53I3 tumor protein p53 inducible protein 3 4.05 
ODZ4 teneurin transmembrane protein 4 4.05 
CTPS CTP synthase 1 4.03 
ESM1 endothelial cell-specific molecule 1 3.97 
FNDC1 fibronectin type III domain containing 1 3.81 
ELN elastin 3.79 
TSPAN13 tetraspanin 13 3.72 
XYLT1 xylosyltransferase I 3.70 
STS-1 ubiquitin associated and SH3 domain containing B 3.66 
LRRN3 leucine rich repeat neuronal 3 3.63 
LMCD1 LIM and cysteine-rich domains 1 3.60 
CD55 CD55 molecule, decay accelerating factor for complement 3.53 
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(Cromer blood group) 
GADD45B growth arrest and DNA-damage-inducible, beta 3.53 
PI16 peptidase inhibitor 16 3.48 
COMP cartilage oligomeric matrix protein 3.48 
COL7A1 collagen, type VII, alpha 1 3.47 
APCDD1L adenomatosis polyposis coli down-regulated 1-like 3.40 
ZPLD1 zona pellucida-like domain containing 1 3.39 
ACTA2 actin, alpha 2, smooth muscle, aorta 3.39 
IVNS1ABP influenza virus NS1A binding protein 3.33 
ENC1 ectodermal-neural cortex 1 (with BTB-like domain) 3.30 
KRT7 keratin 7 3.26 
CSRP2 cysteine and glycine-rich protein 2 3.24 
LAMC2 laminin, gamma 2 3.13 
SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 3.08 
PMEPA1 prostate transmembrane protein, androgen induced 1 3.08 
P4HA2 prolyl 4-hydroxylase, alpha polypeptide II 3.08 
LOC399942 tubulin, alpha pseudogene 2 3.06 
GLS glutaminase 3.05 
CCDC99 spindle apparatus coiled-coil protein 1 3.04 
BHLHB2 basic helix-loop-helix family, member e40 3.04 
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COTL1 coactosin-like 1 (Dictyostelium) 3.01 
SGK1 serum/glucocorticoid regulated kinase 1 3.01 
ACTN1 actinin, alpha 1 3.00 
VCAN versican 3.00 
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 2.99 
NOX4 NADPH oxidase 4 2.99 
PPME1 protein phosphatase methylesterase 1 2.98 
F3 coagulation factor III (thromboplastin, tissue factor) 2.96 
LANCL2 LanC lantibiotic synthetase component C-like 2 (bacterial) 2.95 
PAWR PRKC, apoptosis, WT1, regulator 2.94 
PPP1R13L protein phosphatase 1, regulatory subunit 13 like 2.91 
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 2.90 
UCK2 uridine-cytidine kinase 2 2.90 
FZD8 frizzled family receptor 8 2.90 
IL6 interleukin 6 (interferon, beta 2) 2.90 
CTGF connective tissue growth factor 2.89 
SGK serum/glucocorticoid regulated kinase 2.88 
TUBB6 tubulin, beta 6 class V 2.87 
GLIPR1 GLI pathogenesis-related 1 2.85 
PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 2.81 
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TUBB3 tubulin, beta 3 class V 2.78 
LOC402221 actin, beta pseudogene 2.76 
EDN1 endothelin 1 2.73 
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+  
dependent) 2, methenyltetrahydrofolate cyclohydrolase 
2.70 
C6ORF145 PX domain containing 1 2.66 
DSP desmoplakin 2.64 
ODC1 ornithine decarboxylase 1 2.63 
DSE dermatan sulfate epimerase 2.63 
CSRP1 cysteine and glycine-rich protein 1 2.62 
SERTAD4 SERTA domain containing 4 2.60 
MT1X metallothionein 1X 2.59 
SRM spermidine synthase 2.58 
SPHK1 sphingosine kinase 1 2.55 
MICAL2 microtubule associated monooxygenase, calponin and LIM 
domain containing 
2.55 
DKK1 dickkopf 1 homolog (Xenopus laevis) 2.55 
C1ORF133 SERTAD4 antisense RNA 1 2.54 
TSPAN2 tetraspanin 2 2.52 
WNT5B wingless-type MMTV integration site family, member 5B 2.50 
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NTM neurotrimin 2.50 
ITGA1 integrin, alpha 1 2.49 
ODZ3 teneurin transmembrane protein 3 2.48 
DDAH1 dimethylarginine dimethylaminohydrolase 1 2.47 
PDLIM7 PDZ and LIM domain 7 (enigma) 2.47 
CYR61 cysteine-rich, angiogenic inducer, 61 2.46 
GOLSYN Syntabulin 2.46 
BCAT1 Branched-chain-amino-acid aminotransferase, cytosolic 2.45 
MGC16121 uncharacterized protein MGC16121 2.44 
PFKP PFKP protein 2.44 
DYRK2 Dual specificity tyrosine-phosphorylation-regulated kinase 2 2.41 
NP Transgelin-3 2.41 
PRPS1 Ribose-phosphate pyrophosphokinase 1 2.40 
SLC7A1 High affinity cationic amino acid transporter 1 2.40 
SLC35F2 Solute carrier family 35 member F2 2.39 
LOC729768 Uncharacterized protein 2.39 
CSMD2 CSMD2 protein 2.38 
MYOZ1 myozenin 1 2.37 
PGM2L1 Glucose 1,6-bisphosphate synthase 2.36 
FABP5L2 fatty acid binding protein 5 pseudogene 2 2.36 
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TFPI2 Tissue factor pathway inhibitor 2 2.36 
NPPB Natriuretic peptides B 2.34 
SERPINB2 Plasminogen activator inhibitor 2 2.32 
PDCD1LG2 Programmed cell death 1 ligand 2 2.32 
C6ORF85 Solute carrier family 22 member 23 2.30 
ITGA11 Integrin alpha-11 2.29 
LMO4 LIM domain transcription factor LMO4 2.28 
TUBB2A tubulin, beta 2A class IIa 2.28 
ARL4A ADP-ribosylation factor-like 4A 2.27 
NUAK1 NUAK family, SNF1-like kinase, 1 2.26 
CHN1 chimerin 1 2.26 
DDX21 DEAD (Asp-Glu-Ala-Asp) box helicase 21 2.26 
LOXL3 lysyl oxidase-like 3 2.26 
GALNT10 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 
2.26 
VIL2 ezrin 2.26 
PLAUR plasminogen activator, urokinase receptor 2.25 
SRPX2 Sushi repeat-containing protein SRPX2 2.24 
EFHD1 EF-hand domain family, member D1 2.24 
TMEM158 transmembrane protein 158 (gene/pseudogene) 2.23 
                    
           
 
162 
 
GFPT1 glutamine--fructose-6-phosphate transaminase 1 2.23 
EFNB2 ephrin-B2 2.23 
RUSC2 RUN and SH3 domain containing 2 2.23 
PSME4 proteasome (prosome, macropain) activator subunit 4 2.23 
IGFBP3 insulin-like growth factor binding protein 3 2.23 
HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 2.23 
SDC1 syndecan 1 2.22 
LOC728285 Uncharacterized protein 2.21 
CALB2 calbindin 2 2.21 
E2F7 E2F transcription factor 7 2.19 
GALNTL4 Putative polypeptide N-acetylgalactosaminyltransferase-like 
protein 4 
2.19 
GPC4 glypican 4 2.19 
EZR ezrin 2.19 
KIAA1539 family with sequence similarity 214, member B 2.18 
FERMT2 fermitin family member 2 2.18 
LOC441019 Uncharacterized protein 2.17 
F2RL1 Proteinase-activated receptor 2 2.16 
POTEF POTE ankyrin domain family, member F 2.16 
TAGLN transgelin 2.16 
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SCHIP1 schwannomin interacting protein 1 2.15 
ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix 
protein 
2.14 
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 2.14 
PSMD2 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 2.14 
 
SRF serum response factor 2.13 
RAB3B member RAS oncogene family 2.13 
LOC100134265 Uncharacterized protein 2.12 
ANKRD37 ankyrin repeat domain 37 2.12 
CREB3L2 cAMP responsive element binding protein 3-like 2 2.11 
MSN moesin 2.10 
ULBP2 UL16 binding protein 2 2.10 
SPOCD1 SPOC domain containing 1 2.10 
ARMET mesencephalic astrocyte-derived neurotrophic factor 2.10 
UHRF1 ubiquitin-like with PHD and ring finger domains 1 2.10 
IL7R interleukin 7 receptor 2.10 
BAIAP2L1 BAI1-associated protein 2-like 1 2.09 
PGM3 phosphoglucomutase 3 2.09 
SDF2L1 stromal cell-derived factor 2-like 1 2.09 
PPAPDC1A phosphatidic acid phosphatase type 2 domain containing 1A 2.08 
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COL4A2 collagen, type IV, alpha 2 2.08 
DCBLD1 discoidin, CUB and LCCL domain containing 1 2.07 
HYOU1 hypoxia up-regulated 1 2.07 
PCDH19 protocadherin 19 2.07 
LRRC2 leucine rich repeat containing 2 2.06 
TNS1 tensin 1 2.06 
CHSY3 chondroitin sulfate synthase 3 2.06 
LOC92755 tubulin, beta pseudogene 1 2.06 
TDG thymine-DNA glycosylase 2.05 
PDLIM5 PDZ and LIM domain 5 2.05 
MEX3B mex-3 homolog B (C. elegans) 2.05 
LOC730417 Uncharacterized protein 2.05 
LARGE like-glycosyltransferase 2.04 
FAM101B family with sequence similarity 101, member B 2.04 
BOP1 block of proliferation 1 2.03 
COL22A1 collagen, type XXII, alpha 1 2.03 
CAP1 CAP, adenylate cyclase-associated protein 1 (yeast) 2.03 
MFAP5 microfibrillar associated protein 5 2.02 
RBM24 RNA binding motif protein 24 2.02 
SLC39A14 solute carrier family 39 (zinc transporter), member 14 2.01 
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ECGF1 thymidine phosphorylase 2.01 
ACLY ATP citrate lyase 2.01 
UCN2 urocortin 2 2.01 
SRPRB signal recognition particle receptor, B subunit 2.01 
MTE metallothionein 1I, pseudogene 2.00 
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Appendix ID. Gene down-regulated more than 2 fold in pterygial fibroblasts by TGFβ2  
Symbol               Gene Fold change 
ADH1A alcohol dehydrogenase 1A (class I), alpha polypeptide 0.09 
KIAA1199 Protein KIAA1199 0.11 
RCAN2 regulator of calcineurin 2 0.13 
COLEC12 collectin sub-family member 12 0.18 
AKR1C3 aldo-keto reductase family 1, member C3 0.18 
RAB7B RAB7B, member RAS oncogene family 0.19 
CCL2 chemokine (C-C motif) ligand 2 0.19 
GAS1 growth arrest-specific 1 0.20 
EPHB6 EPH receptor B6 0.21 
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide 0.21 
ANGPTL2 angiopoietin-like 2 0.22 
SLC2A12 solute carrier family 2, member 12 0.22 
SDPR serum deprivation response 0.22 
ADM adrenomedullin 0.22 
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b 0.23 
OSR2 odd-skipped related 2 (Drosophila) 0.25 
SVIL supervillin 0.25 
TGFBR3 transforming growth factor, beta receptor III 0.25 
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RARRES3 retinoic acid receptor responder (tazarotene induced) 3 0.26 
TNFRSF19 tumor necrosis factor receptor superfamily, member 19 0.26 
CLDN11 claudin 11 0.27 
PAMR1 peptidase domain containing associated with muscle 
regeneration 1 
0.27 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 0.27 
TKT transketolase 0.27 
NTN4 netrin 4 0.28 
CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4 0.28 
DHOUR3 dehydrogenase/reductase (SDR family) member 3 0.28 
TMEM140 transmembrane protein 140 0.28 
SMAD3 SMAD family member 3 0.29 
AKR1C4 aldo-keto reductase family 1, member C4 0.29 
PDE7B phosphodiesterase 7B 0.30 
PTGIS prostaglandin I2 (prostacyclin) synthase 0.30 
SOX15 SRY (sex determining region Y)-box 15 0.31 
RABGAP1 RAB GTPase activating protein 1 0.31 
CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 0.31 
GBP2 guanylate binding protein 2, interferon-inducible 0.32 
TMEM119 transmembrane protein 119 0.33 
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LDB2 LIM domain binding 2 0.33 
APOD apolipoprotein D 0.33 
IFITM1 Interferon-induced transmembrane protein 1 0.34 
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 0.34 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 0.34 
TNFRSF14 tumor necrosis factor receptor superfamily, member 14 0.35 
DBC1 deleted in bladder cancer 1 0.35 
CXCL12 chemokine (C-X-C motif) ligand 12 0.35 
C4ORF49 OSAP mitochondria-localized glutamic acid-rich protein 0.35 
CPA4 carboxypeptidase A4 0.35 
TCEA3 Transcription elongation factor A protein 3 0.36 
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2 
0.36 
UBA7 ubiquitin-like modifier activating enzyme 7 0.36 
CTSK cathepsin K 0.36 
EPHX1 epoxide hydrolase 1, microsomal (xenobiotic) 0.36 
SLC15A3 solute carrier family 15, member 3 0.36 
PTGES prostaglandin E synthase 0.37 
C3ORF72 chromosome 3 open reading frame 72 0.37 
ALDH3A1 aldehyde dehydrogenase 3 family, member A1 0.37 
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PPL periplakin 0.37 
ADRA1B adrenoceptor alpha 1B 0.37 
BIN1 bridging integrator 1 0.37 
CYBRD1 cytochrome b reductase 1 0.37 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 0.37 
SEMA6A sema domain, transmembrane domain (TM),  
and cytoplasmic domain, (semaphorin) 6A 
0.37 
TFPI tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor) 
0.38 
RNASET2 ribonuclease T2 0.38 
UBE2L6 ubiquitin-conjugating enzyme E2L 6 0.38 
CD248 CD248 molecule, endosialin 0.38 
PYCARD PYD and CARD domain containing 0.38 
VIT vitrin 0.38 
TSHZ2 teashirt zinc finger homeobox 2 
0.39 
FLT3LG fms-related tyrosine kinase 3 ligand 0.39 
S1PR3 sphingosine-1-phosphate receptor 3 0.39 
MRGPRF MAS-related GPR, member F 0.40 
CRABP2 cellular retinoic acid binding protein 2 0.40 
CMBL carboxymethylenebutenolidase homolog (Pseudomonas) 0.40 
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GYPC glycophorin C (Gerbich blood group 0.40 
PCDH18 protocadherin 18 0.40 
HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent) 0.40 
SLC9A9 solute carrier family 9, subfamily A (NHE9, cation proton 
antiporter 9), member 9 
0.40 
C13ORF15 regulator of cell cycle 0.40 
PLSCR4 phospholipid scramblase 4 0.40 
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 0.41 
GSTM5 glutathione S-transferase mu 5 0.41 
SVEP1 sushi, von Willebrand factor type A, EGF and pentraxin  
domain containing 1 
0.42 
AKAP12 A kinase (PRKA) anchor protein 12 0.42 
MXD4 Max dimerization protein 4 0.42 
EDNRA endothelin receptor type A 0.42 
RDH10 retinol dehydrogenase 10 (all-trans) 0.42 
NQO1 NAD(P)H dehydrogenase, quinone 1 0.42 
CROT carnitine O-octanoyltransferase 0.42 
DYNC2H1 dynein, cytoplasmic 2, heavy chain 1 0.42 
CLIC6 chloride intracellular channel 6 0.42 
PLEKHG4 pleckstrin homology domain containing, family G 0.43 
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(with RhoGef domain) member 4 
SCARA5 scavenger receptor class A, member 5 (putative) 0.43 
IGFBP4 insulin-like growth factor binding protein 4 0.43 
PPAP2B phosphatidic acid phosphatase type 2B 0.43 
NOV nephroblastoma overexpressed 0.43 
JAG1 jagged 1 0.43 
IRF1 interferon regulatory factor 1 0.43 
HS.20255 unkown 0.43 
LAMA4 laminin, alpha 4 0.43 
CAPN5 calpain 5 0.43 
TBC1D2B TBC1 domain family, member 2B 0.44 
GPNMB glycoprotein (transmembrane) nmb 0.44 
C10ORF33 pyridine nucleotide-disulphide oxidoreductase domain 2 0.44 
MX1 myxovirus (influenza virus) resistance 1, interferon-inducible 
protein p78 (mouse) 
0.44 
PCYOX1 prenylcysteine oxidase 1 0.44 
PDGFRA platelet-derived growth factor receptor, alpha polypeptide 0.44 
NUDT7 nudix (nucleoside diphosphate linked moiety X)-type motif 7 0.44 
SLC40A1 solute carrier family 40 (iron-regulated transporter), 
member 1 
0.44 
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ZNF581 zinc finger protein 581c 0.45 
ANKRD35 ankyrin repeat domain 35 0.45 
C10ORF10 chromosome 10 open reading frame 10 0.45 
ZNF395 zinc finger protein 395 0.45 
PGBD3 
piggyBac transposable element derived 3 
0.45 
PIR pirin (iron-binding nuclear protein) 0.45 
LPIN1 lipin 1 0.45 
TMEM130 transmembrane protein 130 0.45 
GSTM3 glutathione S-transferase mu 3 (brain) 0.45 
SELENBP1 selenium binding protein 1 0.45 
QPRT quinolinate phosphoribosyltransferase 0.45 
CLDN23 claudin 23 0.45 
MYLIP myosin regulatory light chain interacting protein 0.45 
CASP1 caspase 1, apoptosis-related cysteine peptidase 0.45 
CYB5A cytochrome b5 type A (microsomal) 0.46 
CARD10 caspase recruitment domain family, member 10 0.46 
PLEKHA4 pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 4 
0.46 
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 0.46 
B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase,  0.46 
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polypeptide 4 
ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5 0.46 
ERRFI1 ERBB receptor feedback inhibitor 1 0.46 
DRAM1 DNA-damage regulated autophagy modulator 1 0.46 
KCNJ2 potassium inwardly-rectifying channel, subfamily J,  
member 2 
0.46 
GMDS GDP-mannose 4,6-dehydratase 0.46 
SEMA3A sema domain, immunoglobulin domain (Ig),  
short basic domain, secreted, (semaphorin) 3A 
0.46 
EXPH5 exophilin 5 0.46 
GSTM2 glutathione S-transferase mu 2 (muscle) 0.46 
MAOA monoamine oxidase A 0.46 
PARP14 poly (ADP-ribose) polymerase family, member 14 0.47 
FNBP1 formin binding protein 1 0.47 
MN1 meningioma (disrupted in balanced translocation) 1 0.47 
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 0.47 
SNORD13 small nucleolar RNA, C/D box 13 0.47 
PARP9 poly (ADP-ribose) polymerase family, member 9 0.47 
C5ORF41 CREB3 regulatory factor 0.47 
OKL38 oxidative stress induced growth inhibitor 1 0.47 
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RND3 Rho family GTPase 3 0.47 
AKR1C2 aldo-keto reductase family 1, member C2 0.47 
C13ORF33 mesenteric estrogen-dependent adipogenesis 0.47 
PNMA2 paraneoplastic Ma antigen 2 0.47 
HS.552087 slit homolog 3 (Drosophila) 0.47 
ANKDD1A ankyrin repeat and death domain containing 1A 0.47 
KRTAP1-5 
keratin associated protein 1-5 0.48 
ADRA2A adrenoceptor alpha 2A 0.48 
SEMA5A sema domain, seven thrombospondin repeats (type 1 and  
type 1-like), transmembrane domain (TM) and  
short cytoplasmic domain, (semaphorin) 5A 
0.48 
PLEKHA6 pleckstrin homology domain containing, family A member 6 0.48 
ZNF423 zinc finger protein 423 0.48 
AMOT angiomotin 0.48 
ATP8B4 ATPase, class I, type 8B, member 4 0.48 
PSMB10 proteasome (prosome, macropain) subunit, beta type, 10 0.48 
GSTM1 glutathione S-transferase mu 1 0.48 
GPR177 wntless homolog (Drosophila) 0.48 
SULF1 sulfatase 1 0.48 
PDE5A phosphodiesterase 5A, cGMP-specific 0.48 
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ALDH3B1 aldehyde dehydrogenase 3 family, member B1 0.48 
TRIM22 tripartite motif containing 22 0.48 
CTSF cathepsin F 0.48 
C5 complement component 5 0.48 
CA12 carbonic anhydrase XII 0.48 
PTGR1 prostaglandin reductase 1 0.48 
CNKSR3 CNKSR family member 3 0.48 
ABCA1 
ATP-binding cassette, sub-family A (ABC1), member 1 0.49 
TXNRD1 thioredoxin reductase 1 0.49 
SLC27A3 solute carrier family 27 (fatty acid transporter), member 3 0.49 
CCDC102A coiled-coil domain containing 102A 0.49 
ACOX2 acyl-CoA oxidase 2, branched chain 0.49 
RAP1GAP RAP1 GTPase activating protein 0.49 
CPXM2 carboxypeptidase X (M14 family), member 2 0.49 
CAT catalase 0.49 
OLFML2B olfactomedin-like 2B 0.49 
REV3L REV3-like, polymerase (DNA directed), zeta, catalytic subunit 0.49 
LOC100133999 unkown 0.49 
RHOBTB3 Rho-related BTB domain containing 3 0.49 
OLFML1 olfactomedin-like 1 0.49 
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SPRY1 sprouty homolog 1, antagonist of FGF signalling (Drosophila) 0.50 
OLFML3 olfactomedin-like 3 0.50 
PDGFD platelet derived growth factor D 0.50 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 0.50 
PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 0.50 
CFD complement factor D (adipsin) 0.50 
STAT1 signal transducer and activator of transcription 1, 91kDa 0.50 
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APPENDIX II 
Proteome profiler: human angiogenesis array   
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Serum maintained control
experiment1 
experiment2 
experiment3 
 
 
TGFβ2 (1ng/ml)
experiment1 
control
experiment2 
experiment3 
 
 
Array images of detectable protein spots in the X-RAY film. Proteome profile of 
angiogenic factors released from pterygial-derived fibroblasts maintained in the 
presence or absence of 10% serum or 1ng/ml TGFβ2 for a 24 hour period. 
 
